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ABSTRACT 
 
 Dengue virus (DENV) is maintained in a primarily anthroponotic cycle between humans 
and the mosquito, Aedes aegypti.  Investigations into DENV infection of the vertebrate host 
generally do not account for the contribution of vector saliva, an inherent part of the mosquito-
borne viral inoculum.  Feeding by mosquitoes on vertebrate hosts is initiated by probing, which 
results in physical damage to the skin and vasculature, and the simultaneous introduction of 
DENV and saliva into the skin.  Saliva contains many individual proteins with the potential to 
modulate host hemostasis and immune responses, thereby facilitating blood feeding and virus 
transmission.  As exogenous antigens, both DENV and these salivary proteins encounter the 
vertebrate host immune system and consequently could have an effect on the immunological 
environment and response of the bite site during viral establishment, as well as the ensuing 
viremia.  My overarching hypothesis is that mosquito saliva aids in the establishment of DENV 
infections within the vertebrate, and that distinct immunological alterations involved in this 
enhancement will be attributable to individual salivary proteins.  I therefore conducted 
investigations into the triad of vector-virus-vertebrate interactions aimed at further characterizing 
1) the strain-based impact of DENV infection on salivary protein transcript expression in Ae. 
aegypti; 2) the probing-based modulation of vertebrate immune responses during DENV 
infection in the skin of a murine model of transmission; 3) the effect of individual salivary 
proteins on DENV production in a human hematopoietic cell line; and 4) the influence of the 
salivary protein ‘aegyptin’ on DENV infection in the mouse; with emphasis on early, 
establishment-relevant time points and differences in infection kinetics with the potential to alter 
transmission success. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 General virology 
 Dengue virus (DENV) is a member of the genus Flavivirus in the family Flaviviridae.  
The genome of DENV is a positive sense, single-stranded RNA of approximately 11kb in length.  
During replication within a host cell, the viral RNA is translated as a single polyprotein that is 
co- and post-translationally cleaved into ten individual proteins: three structural (capsid, 
envelope, pre-membrane) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
NS5).  There are four serotypes of DENV, numbered 1, 2, 3, and 4.  DENV serotype 2 (DENV2) 
is the subject of the novel investigations presented in this dissertation. 
 Mosquitoes also transmit other viruses.  There are three main families to which most of 
these viruses belong: Bunyaviridae, Togaviridae, and Flaviviridae.  Bunyaviruses are enveloped 
with negative-sense, single-stranded, tripartite RNA genomes.  Alphaviruses (Togaviridae) are 
enveloped with positive-sense, single-stranded RNA genomes. Many of these viruses are 
included below in the sections on modification of viral infection and immune response by saliva. 
 
1.2 Epidemiology 
 DENV is the etiologic agent of dengue fever.  DENV prevalence has increased in recent 
decades, and estimates place the global incidence at 390 million annual human infections, of 
which 96 million are clinically or subclinically apparent [1].  Prior to 2009, clinical presentation 
of DENV disease was classified into one of three categories, progressing from mildest to most 
severe: undifferentiated fever, dengue fever, and dengue hemorrhagic fever; dengue hemorrhagic 
fever was further characterized into four grades, with grades III and IV termed dengue shock 
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syndrome.  In 2009, the World Health Organization reorganized these classifications, 
maintaining three categories: dengue without warning signs, dengue with warning signs, and 
severe dengue [2].  Signs and symptoms include fever, nausea, vomiting, rash, aches, and 
leukopenia, with warning signs including persistent vomiting, pleural effusion, ascites, lethargy, 
and swollen liver.  DENV disease is considered severe once one of the following is evident: 
plasma leakage leading to shock, fluid accumulation with respiratory distress, severe bleeding, 
elevated liver enzymes (>1000), central nervous system impairment, and organ failure [3].  From 
2001-2005, DENV disease resulted in an estimated financial burden of  USD $440 million across 
eight countries in the Americas and Asia [4].  The health burden of DENV in Asia and the 
Americas was estimated at approximately 1300 disability-adjusted life years per million in 
population in 2010 [5].   
 
1.3 Transmission 
 DENV is an anthroponotic arbovirus, meaning that it is perpetuated in a transmission 
cycle between humans (the vertebrate) and an arthropod vector (Figure 1.1).  The primary vector 
of DENV is the mosquito Aedes aegypti, with additional transmission events attributed to other 
species in the genus Aedes (e.g., Ae. albopictus) [2].  Transmission from an infectious female 
mosquito to a human is achieved during blood meal acquisition [6].  Feeding by the mosquito is 
initiated by probing, which is the insertion of the stylet fascicle into the skin of the vertebrate in 
search of a capillary.  Probing results in damage to the epithelium and vasculature, and is 
punctuated by expectoration of saliva containing DENV and numerous individual salivary 
proteins.  Saliva and virus is deposited into the vertebrate skin, primarily within the dermal layer 
[7].  After the intrinsic incubation period, when virus has replicated and disseminated throughout  
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Figure 1.1: Transmission cycle of dengue virus.  DENV is perpetuated in a cycle of acquisition, 
dissemination, and deposition between humans and the mosquito vector, Aedes aegypti. 
 
the vertebrate to the point of freely circulating virus particles in the blood (viremia), transmission 
back to the mosquito is possible.  Once again the virus is transmitted during acquisition of a 
blood meal, this time from vertebrate blood to mosquito [8].  After the extrinsic incubation 
period, when virus has overcome numerous physical and physiological barriers within the 
mosquito and disseminated to the salivary gland lumen, the transmission cycle as outlined here 
can begin again [9]. 
 
acq
uisi'
on* deposi'on*
deposi'on* ac
quis
i'on
*
dissemina'on*
dissemina'on*
	   4	  
1.4 Viral deposition 
 Multiple investigations have shown that infectious mosquitoes inoculate their pathogens 
substantially, if not primarily, into the extravascular tissue of the vertebrate.  Seminal work by 
Griffiths and Gordon observed and photographed the process of feeding by Ae. aegypti on the ear 
of a mouse, stating that once the fascicle has passed the epidermis, prior to the tapping of a blood 
vessel, salivation occurred at regular intervals during probing as puffs of clear liquid that would 
immediately disperse [7].  In another study, four species of West Nile virus (WNV, Flaviviridae, 
Flavivirus)-infectious mosquito – Culex tarsalis, Cx. pipiens, Ae. japonicus, and Ae. triseriatus – 
were allowed to probe on a demarcated section of mouse tail.  Immediately following probing, 
the mice were euthanized and the tails were removed.  Greater than 99% of the WNV recovered 
was found within the probed, one centimeter long section of tail, with only small amounts of 
virus recovered from circulating blood [10].  Similarly, when the tails of mice were fed upon by 
Rift Valley fever virus (RVFV, Bunyaviridae, Phlebovirus)-infectious Cx. pipiens and then 
amputated within five minutes post feeding, only 28% of mice died within 72 hours as compared 
to 92% mortality in the group not receiving amputations [11].   While these investigations do not 
specifically exclude viral delivery to the epidermis and subcutaneous layer, it seems likely that 
the salivary and viral inoculum would primarily interact with cells of the dermis. 
 
1.5 Structure of the skin 
 Mammalian skin is primarily divided into two layers, the epidermis and the dermis, that 
lie upon a subcutaneous layer primarily composed of adipose tissue.  The epidermis is 
subdivided into four additional layers: stratum corneum, stratum granulosum, stratum spinosum, 
and stratum basale, which is attached to a basement membrane.  The epidermis is avascular, and 
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is primarily composed of keratinocytes, which contain pattern recognition receptors and are 
capable of producing cytokines, chemokines, and antimicrobial peptides.  The epidermis also 
contains a few specialized immune cell types, such as Langerhans cells and γδT cells.  Below the 
epidermis is the dermis, a highly vascular tissue in which the draining lymphatics also begin.  
This layer houses numerous resident immune cell types with the potential to interfere with the 
establishment of a viral infection, including fibroblasts, multiple subtypes of dendritic cells, 
macrophages, mast cells, γδT and αβT cells, and NK cells.  Upon activation by antigen such as 
that from salivary proteins or virus, the antigen presenting cells in these layers mature and 
migrate through the draining lymphatics to the lymph nodes, potentially spreading virus 
throughout the body [12]. 
 
1.6 Vector saliva  
 Arthropod saliva has been the subject of numerous investigations regarding protein 
composition, functions in blood meal acquisition, and the impact of saliva on vertebrate immune 
responses.  These investigations encompass the gamut of pathogen-transmitting, ectoparasite 
arthropod species, including ticks, black flies, sand flies, and mosquitoes [13].  While valuable 
insights and advances have been achieved through the study of this array of species, the scope of 
this review shall focus on mosquitoes of the subfamily Culicinae, particularly the genera Culex 
and Aedes.   
 
1.6.1 Composition of saliva and blood meal acquisition 
 The mosquito sialome (salivary transcriptome + proteome) has been well characterized in 
terms of protein families and broad functionality.  Saliva is known to be antihemostatic, 
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containing proteins that can inhibit clotting, platelet aggregation, and vasoconstriction for the 
purpose of aiding blood meal acquisition [13].  Among the protein groups of Ae. aegypti are D7s, 
which have been shown to inhibit biogenic amines; protease inhibitors, including serpins; 
enzymes, including serine proteases and nucleotidases such as apyrase and adenosine deaminase; 
immunity-related proteins such as C-type lectins, angiopoietins, a defensin, and a putative 
lysozyme; and a myriad of other proteins described only by their putative size or homology [14, 
15].  Additionally, recent studies have described the impact of DENV infection on protein 
expression in the salivary glands and expectorated saliva of Ae. aegypti and postulates how these 
changes might affect virus transmission and establishment within the vertebrate [16, 17].  
Among the proteins found in lower abundance were an adenosine deaminase and an aegyptin 
(discussed below) [17].  The decreased expression of these proteins during DENV infection 
could suggest that they impart negative pressure on viral perpetuation, and as such these proteins, 
along with a putative C-type lectin, were chosen for investigations herein with regard to their 
impact on DENV infection of the vertebrate.  As exogenous antigen, both salivary proteins and 
virus encounter the vertebrate host immune system and consequently can influence the 
immunological environment of the bite site during viral establishment and infection. 
 
1.6.2 – Methods and hurdles of investigation 
 There exists a great deal of variability and in some cases outright contradiction among the 
data discussed herein regarding salivary modulation of the vertebrate immune response and 
infection.  At present, the confounding factors in existing publications are too numerous to 
identify the root of this variability, but there are several candidates for consideration.  The 
following tables display many of the possible sources of variability in experimental approach to 
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examine salivary modulation of the immune response.  The enumerations are taken from 
publications discussed and cited in the sections below.  
 There are several methods for introducing mosquito saliva and its related mosquito 
components into a model system, each with its pros and cons (Tables 1.1 and 1.2).  In infectious 
mosquito delivery, mosquitoes (that have either imbibed a blood meal containing virus or have 
been intra-thoracically inoculated with virus and now have an infection that has disseminated to 
the salivary glands) are allowed to feed on the vertebrate to initiate infection.  This is by far the 
most natural system, but the quantity of saliva and virus expectorated into each vertebrate is 
difficult to know and impossible to standardize.  In spot-feeding, a naïve (non-infectious, non-
exposed) mosquito is allowed to feed on a restricted area of skin and then a known concentration 
of virus is needle-inoculated into the location of feeding (or in one instance, immediately prior to 
feeding).  The time between feeding and inoculation is usually kept to a minimum, but is 
occasionally of considerable length.  Spot-feeding allows for the delivery of a known, pre-
determined quantity and volume of virus, but the quantity of saliva delivered is still not 
standardized.  The uninfected mosquito category is the same as that of the spot-feeding method, 
with the exception that there is no subsequent viral inoculation.  Salivary gland extract or 
salivary gland homogenate (SGE) is generated by CO2- or cold-anesthetizing female mosquitoes, 
dissecting out the salivary glands, and homogenizing the glands in a physiological buffer.  The 
SGE is then needle-inoculated into the vertebrate skin, with or without virus in the same syringe.  
The SGE method includes additional, intracellular proteins and other components of the salivary 
glands themselves that are not typically introduced to the vertebrate upon feeding and therefore 
could alter the vertebrate infection and immune response in unnatural ways.  The volume of 
actual secreted saliva proteins relative to the inoculum is also not known, but with this and all 
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subsequent needle-inoculation methods, the volume and concentration of virus delivery is easily 
standardized.  Collection of saliva is achieved by prompting female mosquitoes to salivate into a 
physiological saline buffer or mineral oil held within a capillary tube or artificial feeding 
apparatus.  This saliva is then collected, pooled, sometimes concentrated, and serves as the 
inoculum in much the same manner as SGE.  Collection of saliva is very tedious work and, 
depending on the application, may require vast numbers of mosquitoes to achieve a usable 
quantity.  The saliva method allows for a more natural protein profile in the inoculum than does 
SGE, though some of the smaller or less abundant saliva proteins may be lost during 
concentration.  The recombinant protein method utilizes saliva proteins of known sequence 
expressed in vitro.  This method allows for precise quantitation of the protein and virus 
inoculum, but often assumes native/functional conformation state and post-translational 
modifications, and lacks the influence of other proteins typically found in saliva.  However, 
investigating individual proteins could allow for targeted manipulation of the infection and/or 
immune response for use in therapeutic development or novel vaccination strategies.  The DNA 
vaccine method, published once in this body of literature, utilizes a vaccine vector containing the 
sequence for a specific salivary protein.  This vector is then injected into the vertebrate for the in 
situ production of the saliva protein under investigation.  The pros and cons of this method are 
similar to those of recombinant proteins, with the exception that quantitation of the saliva protein 
utilized is difficult at best and a native/functional protein is less tenable.  The methods discussed 
here that involve needle-inoculation also do not adhere to any one inoculation route, or rather 
depth (Table 1.3), which may have an affect on the subsequent infection and immune response 
given the differing cell types within each skin layer [12, 18].  
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Table 1.1:  Listing and enumeration of the various methods utilized in the published literature to 
introduce the mosquito/saliva variable into the experimental system.   
 
Method # of publications 
Infectious mosquito 11 
Spot-feeding 6 
Uninfected mosquito* 5 
Salivary gland extract† 14 
Saliva 4 
Recombinant Protein 3 
DNA vaccine 1 
* = distinct entries from spot-feeding; utilized in non-infection studies 
† = includes one entry for “thorax extract” 
 
Table 1.2: Relative value of the five main methods of mosquito/salivary involvement in the 
modulation of a viral infection in vivo.  Check marks indicate the magnitude of added value or 
attribution each option would bring to the understanding in the far left column.  Table modified 
from Mores et al, 2014. J Infect Dis. 2014 Jun 15;209. 
 
  Co-inoculation with virus 
 Infectious Mosquito 
Spot-
feeding Saliva SGE Proteins 
Near natural route of 
exposure ✓✓✓ ✓✓ ✓✓ ✓ ✓ 
Calculable / known viral titer ✓ ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
Known concentration of 
salivary inoculum ✓ ✓ ✓✓✓ ✓✓ ✓✓✓ 
Specificity of immune 
response modulation ✓✓ ✓✓ ✓✓ ✓ ✓✓✓ 
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Table 1.3: Listing and enumeration of the route utilized to deliver needle-inoculated salivary 
components to the experimental animal model. 
 
Injection Route # of publications 
Intramuscular 1 
Subcutaneous 3 
Intradermal 6 
 
 Another major factor to consider in the investigations of salivary impact on infection and 
immune response discussed herein is the species and strains of animals used.  In terms of the 
vertebrate animal models, there is considerable diversity among the murine models, with more 
strains being utilized than there are papers utilizing murine models (Table 1.4).  Many of these 
mice are known to have genetic and immunologic predispositions and, in some cases, resistances 
that make the comparison of their data more difficult.  For example, male and female C57BL/6 
mice are known to be predisposed to more prominent innate and adaptive immune responses, 
respectively [19].  C57BL/6 and BALB/c strains have immune responses that are predisposed 
toward TH1 and TH2, respectively [20].  C3H/HeJ mice have hyporesponsive TLR4 [21].  
C57BL/6, BALB/c, and C3H mice have also demonstrated differential susceptibility and 
immune response to viral challenge [22].  Among the seven distinct species of mosquito utilized 
in these investigations, there are at least eleven strains used (and considerably more unspecified; 
Table 1.5).  These mosquitoes have different feeding habits and preferences, and sialome 
variation has been demonstrated among the different colonies [23, 24]. 
  
 
 
	   11	  
Table 1.4: Listing and enumeration of the various murine model strains utilized in investigating 
the effects of mosquito/salivary involvement on the vertebrate immune response.  This table does 
not include the additional model systems utilized: chicken, deer, chipmunk, the non-human 
primate Vero cell line, and primary and immortalized human cell lines. 
 
Mouse strain # of publications 
129 1 
129 IFNAR -/- 1 
BALB/c 2 
BALB/c OVA-TCR DO11 1 
TCR transgenic BALB/c 
Thy1.1 1 
BALB/c Thy1.2 1 
C3H/HeJ 4 
C3H/HeN 1 
C3H/RV (C3H.PRI-Flv) 1 
C57BL/6 3 
C56BL/6-NRJ 1 
C57BL/6 IFNAR -/- 1 
C57BL/6 IRF3/7 -/--/- 1 
CD-1 1 
DBA-1 1 
ICR 2 
NIH Swiss 2 
Swiss Webster 1 
Humanized‡ 1 
‡ = NOD/SCID/IL2Rγ null mice transplanted with human cord blood CD34+ cells 
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Table 1.5: Listing and enumeration of the mosquito species utilized in investigating the effects of 
mosquito/salivary involvement on the vertebrate immune response.  This information includes 
mosquitoes utilized as sources for primary reagents (e.g., SGE).  
 
Mosquito species # of publications 
# using field 
caught 
# using 
colony* 
# of different 
colony strains* 
Remainder 
unspecified 
Aedes aegypti 16 0 8 ≥4 8 
Aedes albopictus 1 0 1 1 0 
Aedes triseriatus 4 1 1 1 2 
Aedes vexans 1 0 0 0 1 
Culex pipiens 4 0 3 ≥1 0 
Culex quinquefasciatus 1 0 1 1 0 
Culex tarsalis 4 0 4 3 1 
* = if a strain designation is used, the publication is considered “colony” 
 
 The most pertinent potential source of variation to the novel investigations presented in 
this dissertation is the diversity among DENV strains utilized in saliva-modulated infection 
models and the very limited number of publications on their investigation (Table 1.6).  With 
regard to DENV2, there are only four publications that experimentally evaluate the impact of 
mosquito/salivary involvement on the vertebrate infection and immune response (with the 
possible addition of two more that do not specify a serotype in the published manuscript).  
Among these four publications, there are seven different strains used: four in one paper, one in 
each of the other three.  These strains vary in their passage history and genetic sequence, which 
makes comparison all the more difficult. 
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Table 1.6: Diversity of DENV strains utilized in the limited number of publications investigating 
the impact of mosquito/salivary involvement on DENV infection and vertebrate immune 
response. 
 
DENV serotype # of pubs # of DENV strains 
DENV1 1 1 
DENV2 4 7 
DENV3 1 1 
DENV4 2 2 
DENV?* 2 ? 
* = unspecified serotype and strain 
 
1.6.3 Impact of saliva in the vertebrate – Cellular modulation 
 Mosquito saliva has been demonstrated to impact vertebrate immune cell functions in 
vitro and in vivo outside the context of an infection.  Ex vivo treatment of murine splenocytes 
with Ae. aegypti SGE reduced antigen-specific (OVA) and non-specific (ConA) splenocyte 
proliferation overall, as well as decreasing CD4+ and CD8+ T-cell proliferation and increasing 
T-cell (both CD4+ and CD8+) and B-cell (B220+) mortality.  In contrast, SGE of Cx. 
quinquefasciatus induced no significant changes [25].  In another ex vivo experiment utilizing 
murine splenocytes, pre-incubation with Ae. aegypti SGE suppressed proliferation of OVA- or 
ConA-stimulated T-cells and LPS-stimulated B cells in a dose-dependent manner.  Additionally, 
higher concentrations of SGE (≥2.5 SGP-equivalents) again significantly decreased CD4+ and 
CD8+ T-cell viability, whereas concentrations tested of up to 25 SGP-equivalents had no effect 
on dendritic cell viability [26].  In contrast, intradermal injections of Ae. aegypti SGE into a 
mouse one hour prior to ID stimulation with antigen resulted in significantly increased 
proliferation of CD4+ cells [27].  Humanized mice bitten by naïve Ae. aegypti exhibited 
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thrombocytopenia as compared to unexposed, control mice [28], and naïve Ae. aegypti feeding 
on the ears of mice induced recruitment of eosinophils to the bite site [29].  In mice vaccinated 
with the recombinant salivary protein D7 of Cx. tarsalis, the bite of naïve mosquitoes resulted in 
increased infiltrating polymorphonuclear and mononuclear cells at the bite site as compared to 
unvaccinated mice [30].  
 
1.6.4 Impact of saliva in the vertebrate – Cytokines, antibodies, & transcripts 
 Mosquito saliva has been demonstrated to impact vertebrate cytokine production in vitro 
and in vivo outside the context of an infection, typically in association with the cellular 
modulations outlined above.  Incubation of monocyte derived dendritic cells in vitro with Ae. 
aegypti saliva resulted in increased production of IL12p70 but had no effect on expression of the 
surface markers CD40, CD83, HLA-ABC, and HLA-DR [31].  Ex vivo treatment of murine 
splenocytes with Ae. aegypti SGE resulted in decreased IFNγ and IL10, whereas Cx. 
quinquefasciatus SGE elicited no change [25].  In an ex vivo experiment utilizing OVA-
stimulated murine splenocytes, pre-incubation with Ae. aegypti SGE resulted in decreased 
production of all cytokines assessed in a dose-dependent manner, with lower concentrations 
suppressing IL2, IL5, IL12, IFNγ, GMCSF, and TNFα, and higher concentrations additionally 
suppressing IL4 and IL10 [26].  In contrast, intradermal inoculation of SGE resulted in increased 
IL4 production at the inoculation site in a mouse [32].  Naïve Ae. aegypti feeding on the ears of 
mice resulted in decreased expression of TLR3 and IFNγ and increased expression of IL4 and 
IL10 in the skin at the bite site, though these differences were not assessed statistically [29].  Ae. 
aegypti bitten mice exhibited significantly increased IL4 at the location of mosquito bite at three 
hours post feeding, but demonstrated no significant alterations in the production of IL2, IL10, 
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IL12p40, IFNγ, and TNFα.  Additional investigations in this study revealed that vaccination with 
a DNA vector containing the sequence for salivary protein SAAG-4 (another designation for the 
short form of aegyptin) induced elevated levels of IL4 and IL10 and decreased levels of 
IL12p40, IFNγ, and TNFα.  Intradermal injections of SGE or the SAAG-4 DNA vector also 
yielded a higher percentage of CD4+ T-cells with positive, intracellular staining for IL4 [27].  
Splenocytes from mice bitten by Cx. pipiens or Ae. aegypti collected over several days post 
feeding and then stimulated with ConA demonstrated a TH2 cytokine shift, characterized by 
increased IL4 and IL10 (days 4-7) followed by decreased IFNγ (days 7-10) with similar effects 
seen for both mosquito species.  These splenocyte cytokine expression patterns were mimicked 
by the injection of mice with the synthesized, salivary peptides sialokinin I and II of Ae. aegypti 
[33].  Splenocytes of mice vaccinated with the recombinant salivary protein D7 of Cx. tarsalis 
produced increased IFNγ and decreased IL10 upon rD7 stimulation two days after the mice 
received naïve mosquito bites as compared to unvaccinated mice.  In contrast, the same study 
produced elevated levels of serum IFNγ in mice at four days post naïve mosquito bite [30].   
 
1.7 Saliva-mediated modulation of viral infection 
 Mosquito saliva has been shown to modulate infection of the vertebrate host by a diverse 
range of viruses.  All modulation described below are from the perspective of simultaneous 
delivery of virus and saliva through the described method versus inoculation of virus alone 
unless otherwise indicated. 
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1.7.1 Cellular modulations & distribution 
 Including mosquito saliva in investigations of viral infection can result in changes to 
cellular viability, recruitment, and general inflammation.  In an in vitro experiment using human 
moDCs derived from primary PBMCs, co-inoculation Ae. aegypti saliva and DENV significantly 
increased cellular survival by decreasing late-stage apoptosis [31].  Co-inoculation of mice with 
SGE and RVFV significantly decreased total leukocyte and platelet counts, though the leukocyte 
differential was unaffected.  Co-inoculation with SGE also resulted in multifocal hepatitis and 
increased neutrophil infiltration to these sites [34].  In a murine model of WNV infection, Ae. 
aegypti spot-feeding reduced T (CD3+) cell recruitment to the bite/inoculation site when 
compared to animals that received only ID injection of WNV, but did not significantly affect the 
recruitment of neutrophils, Langerhans cells, dendritic cells, or macrophages.  There was no 
change elicited to cell recruitment in the draining lymph node [35].  In mice exposed via WNV-
infected mosquito, pre-sensitization to Ae. aegypti saliva increased inoculation site tissue size by 
greater than 200%, exhibiting an increased influx of plasma cells, histiocytic cells, neutrophils, 
and a greater than two-fold increase in MHCII-positive cells as compared to naïve mice.  
Draining lymph nodes displayed marked expansion and increased numbers of MHCII+ cells, 
CD11b+ cells, and decreased numbers of CD3+ cells [36]. 
 
1.7.2 Cytokines, antibodies, & transcripts 
 Much of the work examining the effects of mosquito saliva on viral pathogens suggests 
that there is a shift away from an antiviral, TH1 immune response toward a TH2 response, among 
other immunological alterations, exemplified best in vivo.  In an in vitro experiment using human 
moDCs derived from primary PBMCs, co-inoculation of Ae. aegypti saliva and DENV 
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significantly increased production of IL12p70 and TNFα, but did not alter production of IFNα 
(Ader 2004).  In primary human keratinocytes culture infected with DENV, co-inoculation of Ae. 
aegypti SGE significantly reduced production of β-defensin3, IFNα, IFNβ, IFNγ, LL-37, Elafin, 
and S100A7 [37].  In a second in vitro study utilizing primary human keratinocytes, co-exposure 
of cells with DENV and individual, recombinant salivary proteins of Ae. aegypti, resulted in 
decreased expression of the antiviral and antimicrobial peptide transcripts for IFNα, IFNβ, IRF3, 
IRF7, LL-37, S100A7, and RNase7 depending on the protein and concentration utilized.   The 
four proteins utilized were FXa-directed anticlotting serpin-like protein (GenBank 
Q1HRTV7_AEDAE), an adenosine deaminase (Q179D4_AEDAE), a 34-kDa family secreted 
salivary protein (Q1HRW0_AEDAE), and a putative secreted protein (Q8T9U5_AEDAE), with 
the 34-kDa protein eliciting the most marked decreases [38].  In vitro assessment of murine 
peritoneal macrophages revealed that Ae. aegypti SGE significantly lowered IFNβ, iNOS, and 
IL12 in response to WNV infection, but did not significantly alter levels of IL10, IFNγ, or IL1β.  
As a point of comparison, SGE modulated the response to sindbis virus (SINV, Togaviridae, 
Alphavirus) infection in these cells by lowering IFNβ and iNOS production, and the initial 
elevation and subsequent decrease of IL10 production, with no effect on IFNγ, IL1β, or IL12.  
Bone marrow derived DCs also produced lower IFNβ in vitro as a result of Ae. aegypti SGE 
modulation of WNV infection, but had no effect on production of IFNγ, IL2, IL4, IL12, and 
IL1β [35].  Co-inoculation of Ae. triseriatus SGE and vesicular stomatitis virus (VSV, 
Rhabdoviridae, Vesiculovirus) reduced expression of IFNα2 in the murine fibroblast cell line 
L929 [39].  Co-exposure of the human keratinocyte cell line HaCaT with Ae. albopictus SGE 
and chikungunya virus (CHIKV, Togaviridae, Alphavirus) produced significantly decreased 
levels of IL8 [40].   
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 Delivery of DENV2 by infected Ae. aegypti into humanized mice elicited greater levels 
of circulating IFNγ, IL8, and MCP1 and increased the number of anti-DENV IgM positive 
animals.  Mosquito delivery also reduced temperature, modulated thrombocyte levels compared 
to needle or control, and increased the erythema index.  The feeding of four or more infected 
mosquitoes was required for consistent clinical results in this model [28].  Two methods, ID 
inoculation of DENV2 into humanized mice 30-60 minutes following Ae. aegypti feeding at a 
distal site and ID inoculation of DENV and Ae. aegypti saliva simultaneously,  lowered erythema 
index and increased body temperature compared to mosquito-delivered virus infection, but did 
not significantly affect erythema index or temperature compared to DENV-only treatment.   
However, simultaneous inoculation of saliva and DENV lowered thrombocyte count relative to 
normal on the single reported day, whereas the delayed and distal spot-feeding did not elicit any 
changes to thrombocyte count [28].  
 Delivery of vesicular stomatitis New Jersey virus (VSNJ, Rhabdoviridae, Vesiculovirus) 
to mice by infected Aedes triseriatus increased anti-VSNJ antibody production from 13% to 94% 
in three week old mice and from 11% to 73% in eight month old mice [41].  In a murine model 
of SINV infection, co-inoculation of Ae. aegypti SGE resulted in significantly decreased IFNγ 
and IFNβ with concomitantly increased IL4, IL10, and IL12p40 at the inoculation site [32].  
Similarly, infection of mice via CHIKV-infected Ae. aegypti resulted in significantly increased 
IL4 and IL10 production and decreased production of IFNγ, IL2, and TLR3 [29].  In a murine 
model of WNV infection, Ae. aegypti spot-feeding significantly increased IL10 production in the 
exposed skin and draining lymph node [35].  In mice exposed via WNV-infected mosquito, pre-
sensitization to Ae. aegypti saliva increased production of IL10 in the inoculation site as 
compared to naïve mice, as well as increased IL10 and IL4 in the draining lymph node, though 
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the latter two were not significant [36].  Infected-mosquito delivery of WNV into mice that have 
been vaccinated against the salivary protein D7 of Cx. tarsalis resulted in greater production of 
IL10 and decreased production of IFNγ, TNFα, IL12p70, and MIP1 from ex vivo splenocytes 
when compared to that of unvaccinated mice [30].  In contrast, infected mosquito delivery of 
WNV into mice that have been vaccinated against the SGE of Cx. tarsalis resulted in increased 
IFNγ, TNFα, and IL4 in the spleen and increased anti-WNV neutralizing antibody titers when 
compared to unvaccinated mice [42].   
   
1.7.3 Viral titers in inoculation sites and circulation 
 With a few exceptions included herein, inoculation via mosquito bite and exposure to 
saliva have been shown to enhance viral infection or potentiate infection in otherwise non-
permissive models.  In an in vitro experiment using human moDCs derived from primary 
PBMCs, co-inoculation of Ae. aegypti saliva significantly decreased the percentage of DENV2 
(40%à18%) and DENV4 (38%à18%) infected cells.  Additionally, pre-incubation of moDCs 
with saliva further inhibited infection with DENV4.  Co-inoculation of saliva did not alter yellow 
fever virus (YFV, Flaviviridae, Flavivirus) infection in this system [31].  In contrast, in vitro 
infection of mouse embryonic fibroblasts pre-exposed to SGE for ten minutes revealed increased 
viral RNA in the cells and increased virion production into the supernatant by all four serotypes 
of DENV [43].  Similarly, in an in vitro study utilizing primary human keratinocytes, co-
inoculation of Ae. aegypti SGE significantly increased DENV titers [37].  In a second study 
utilizing primary human keratinocytes, co-exposure of cells with DENV and individual, 
recombinant salivary proteins of Ae. aegypti, resulted in greater concentrations of viral RNA.  
This enhancement occurred at similar levels regardless of the protein tested (listed above in 
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subsection 1.7.2), and may occur in a dose-dependent manner, though this was not assessed 
statistically [38].  Co-exposure of the human keratinocyte cell line HaCaT with Ae. albopictus 
SGE and CHIKV produced significantly increased levels of CHIKV RNA [40].  In an in vitro 
study of VSV infection, co-inoculation of Ae. triseriatus SGE significantly increased production 
of VSV in the murine fibroblast cell line L929, but not in the type I IFN-deficient Vero cell line 
[39].  Interestingly, in vitro assessment revealed that Ae. aegypti SGE had no effect on WNV or 
SINV titers in murine peritoneal macrophages, nor on WNV titers in bone marrow derived DCs 
[35]. 
 Delivery of DENV2 by infected Ae. aegypti into humanized mice resulted in a longer 
duration of viremia, reaching up to 56 days and thereby far exceeding that of a natural human 
infection.  The feeding of four or more infected mosquitoes was required to extend detection of 
circulating viral RNA beyond that of needle inoculation in this model.  Additionally, ID 
inoculation of DENV2 into humanized mice 30-60 minutes following mosquito feeding at a 
distal site resulted in a viremia comparable to that of infected mosquito delivery.  ID inoculation 
of DENV2 and Ae. aegypti saliva simultaneously into humanized mice also resulted in a viremia 
statistically comparable to that of infected mosquito delivery, though it trended lower [28].  In 
contrast, in mice co-inoculated with DENV2 and Ae. aegypti SGE,  no difference was found 
between groups regarding the inoculation site, spleen, or viremia DENV titers at the single time 
point assessed, 24 hours post exposure.  However, DENV titers were found to be significantly 
elevated in the draining lymph node, and this enhancement was found to be significantly 
inhibited by the addition of a serine protease inhibitor [43].   
 Delivery of La Crosse virus (Bunyaviridae, Orthobunyavirus) by infected Ae. triseriatus 
into deer and chipmunks significantly increased the magnitude and duration of viremia when 
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compared to IM needle-inoculation of virus alone [44].  Spot-feeding by naïve Ae. aegypti, Ae. 
triseriatus, or Cx. pipiens on mice potentiated infection of Cache Valley virus (Bunyaviridae, 
Orthobunyavirus) and led to neutralizing antibody production in these otherwise non-permissive 
vertebrates after subcutaneous injection of virus.  This potentiation of infection occurred with up 
to a four hour delay between mosquito feeding and injection, but did not occur when injection of 
virus was administered in a site distal (greater than four centimeters) to the feeding site.  In 
contrast, injection of virus plus “thorax extract” (an SGE approximation) did not lead to infection 
or production of neutralizing antibodies [45].  In mice infected with RVFV, spot-feeding and 
intradermal co-inoculation with SGE led to an earlier median day of death.  Co-inoculation with 
SGE also significantly increased RVFV viremia titers, and titers in the brain, liver, inguinal 
lymph node, spleen, thymus, lungs, kidneys, bladder, and heart.  In contrast, RVFV titers were 
decreased in the cerebellum and pancreas, and unaffected in the mesenteric, aortic, and popliteal 
lymph nodes and salivary glands [34].  Infection of mice via CHIKV-infected Ae. aegypti 
resulted in infiltration of neutrophils and abundant eosinophils to the inoculation site, as 
compared to undetectable recruitment in mice bitten by naïve mosquitoes or those needle-
inoculated with CHIKV alone [29].   
 The bite of WNV-infected Culex spp. significantly increased WNV viremia in chickens 
and increased viral shedding to the oral mucosa and cloaca.  Additionally, chickens bitten by 
multiple infected mosquitoes (n= 3-11) exhibited early viremias with WNV titers far exceeding 
that of a strictly additive or viral dose-dependent effect (25-50 times greater than that resulting 
from a single infected mosquito).  This enhancement is likely attributable to other factors 
involved in viral inoculation, such as the damage caused by probing or the proteins in the 
salivary inoculum [46]. Spot-feeding of mice by Ae. aegypti that are then inoculated 
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intradermally with WNV exhibited viremias with greater magnitude and duration, as well as 
significantly increased WNV titers in the brain.  Spot-feeding decreased survival rates from 
24.9% to 0% in mice inoculated with 102 PFU of WNV, and mice co-inoculated with SGE 
exhibited a survival rate between that of spot-feeding and needle-inoculation alone mice.  Spot-
fed mice also displayed a consistent trend toward elevated WNV titers in the exposed skin and 
draining lymph node, though not significant [47].  In a later study by this group, Ae. aegypti 
spot-feeding significantly increased viral titers in the exposed skin and draining lymph node in a 
murine model of WNV infection [35].  Infection of mice by a single WNV-infected Cx. tarsalis 
resulted in decreased WNV titers at the inoculation site at a single time point (24 hours) post 
exposure, whereas spot-fed mice inoculated subcutaneously initially presented decreased WNV 
titers (below limit of detection) at twelve hours post exposure that then surpassed needle-
inoculation alone titers at 24 hours post exposure.  No differences were observed in the draining 
lymph node in these mice.  Infected-mosquito delivery, spot-feeding, and co-inoculation with 
SGE all resulted in significantly increased WNV viremia titers, up to ten times greater on days 
one and two post exposure, with spot-feeding and SGE extending this elevation to day three post 
exposure.  Spot-feeding and infected-mosquito delivery led to faster dissemination of virus to 
other tissues, a greater proportion of mice experiencing neuroinvasion, and increased WNV titers 
in the spleen and spinal cord.  Additional IV inoculation of WNV did not affect viremia or tissue 
titers, nor was there a notable difference between spot-fed viremia titers and infected mosquito 
viremia titers, suggesting that variations in the location of viral deposition itself did not cause the 
enhancement of WNV in these mice.  SGE inoculation in a site distal to WNV inoculation did 
not lead to enhancement, indicating once again a local effect by SGE on the pathogenesis of 
infection enhancement.  Importantly, spot-fed enhancement still occurred in mice with antibodies 
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against saliva (due to pre-exposure to Cx. tarsalis feeding), with these mice exhibiting two-times 
the WNV viremia of mice without antibodies against saliva at 24 hours post exposure [48].  Pre-
sensitization of mice to Ae. aegypti saliva enhanced WNV titers in the draining lymph node and 
WNV-induced mortality in mice inoculated via infected mosquito when compared to naïve mice.  
Additionally, a greater number of pre-sensitization treatments resulted in greater mortality rates 
[36].  Infected mosquito delivery of WNV into mice that have been vaccinated against the 
salivary protein D7 of Cx. tarsalis resulted in significantly increased mortality when compared to 
unvaccinated mice [30].  In contrast, infected mosquito delivery of WNV into mice that have 
been vaccinated against the SGE of Cx. tarsalis resulted in delayed neuroinvasion, decreased 
WNV titers in the brain, and decreased (zero) mortality when compared to unvaccinated mice 
[42].    
 
1.8 Aegyptins 
 Aegyptins, the subject of the fourth chapter of experimental investigations, are a family 
of GE-rich 30-kDa proteins that possess multiple direct and indirect physiological effects.  There 
are two subclades of these proteins within Aedes, designated subclade I and subclade II.  Prior 
analysis of expectorated saliva from DENV2 infected Ae. aegypti using 2D gel electrophoresis 
and LC-MS/MS identified a subclade I aegyptin (gi|18568322) that was reduced 14.1-fold when 
compared to saliva from uninfected mosquitoes [16].  This aegyptin has also been termed 
“SAAG-4,” and has been shown to suppress IFN-γ expression and increase IL-4 expression by 
CD4+T cells outside the context of a viral infection [27].  The archetypal protein of the aegyptin 
family in Ae. aegypti is a member of subclade II, and has been shown to perform two distinct 
roles within the vertebrate.  First, as an allergen, this protein (termed “Aed a 3,” gi|205525920) 
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has been shown to induce positive skin-test reactions, and IgG and IgE antibody responses in 
sensitized mice and humans [49, 50].  Researchers have also found an association between serum 
reactivity to this protein and the mild DENV disease state in clinical patients in Thailand [51].  
Second, aegyptin (gi|94468546, identical in sequence to Aed a 3) has demonstrated the capacity 
to bind to collagen, inhibiting its interaction with glycoprotein IV, integrin α2β1, and von 
Willebrand factor, which could facilitate blood feeding by reducing the formation of blood clots 
[52, 53].  Indeed, transgenic suppression of aegyptin expression in Ae. aegypti significantly 
reduced blood feeding success.  Probing time increased from a range of 15-21 seconds to a range 
of 78-300 seconds before initiation of successful blood acquisition, and those mosquitoes that did 
feed acquired smaller blood meals [54]. 
 While the two aegyptin groups represent distinct subclades, the acidic (glycine-, aspartic 
acid-, and glutamic acid-rich) aminoterminal domain and the more complex carboxyterminal 
domain characteristic of this protein family remain conserved [13].  Due to the involvement of 
aegyptins with both the vertebrate immune response and hemostasis, we explored the impact of a 
recombinant, subclade II aegyptin on the vertebrate immune response within the context of a 
DENV infection. 
 
1.9 Hypothesis & research overview 
 The overarching hypothesis governing the novel investigations presented in this 
dissertation is that mosquito saliva will aid in the establishment of DENV infections within the 
vertebrate, and that distinct immunological alterations involved in this enhancement will be 
attributable to individual salivary proteins.  I therefore conducted investigations into the triad of 
vector-virus-vertebrate interactions aimed at further characterizing the following: 
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1) the strain-based impact of DENV2 infection on salivary gland protein transcript expression in 
Ae. aegypti.  This is the subject of Chapter II, where high-throughput RNA-sequencing 
technology was implemented to quantify transcriptional abundance in Rockefeller colony 
mosquitoes with disseminated infections.  Potential differences in protein production may 
provide selective advantage to the perpetuation of specific DENV strains through enhancements 
in establishment of infection and in viremia within the vertebrate. 
2) the probing-based modulation of vertebrate immune responses in the skin and the subsequent 
viremia during DENV2 infection of a murine model of transmission.  In Chapter III, modulations 
of the immune response in Ae. aegypti spot-fed inoculation sites of C57BL/6 IRF3/7-/- -/- mice 
were assessed via transcript arrays and targeted qRT-PCR analysis.  These modulations were 
then associated with a greatly enhanced viremia that could potentially support increased 
acquisition rates among naïve mosquitoes.  
3) the effect of individual salivary proteins from Ae. aegypti on DENV2 replication in a human 
hematopoietic cell line.  In Chapter IV, three recombinant salivary proteins with known and 
putative functions (an aegyptin, a C-type lectin, and an adenosine deaminase) were generated 
and co-inoculated alongside DENV2 into K562 cell culture for assessment of DENV2 replication 
kinetics. 
4) the influence of the salivary protein aegyptin on DENV2 infection in the mouse. In Chapter V, 
modulations in the C57BL/6 IRF3/7-/- -/- murine immune response, inoculation site viral titers, 
and viremia due to co-inoculation of DENV2 and recombinant aegyptin were assessed.  The 
results of this investigation provide a rationale for the decreased abundance of aegyptin in the 
expectorated saliva of DENV2-infected Ae. aegypti. 
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 As detailed above, these investigations focus on early, establishment-relevant time points 
regarding DENV2 infection in the vertebrate, and differences in infection kinetics with the 
potential to alter transmission success. 
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CHAPTER 2 
A VIRAL STRAIN-BASED HIGH-THROUGHPUT RNA-SEQUENCING ANALYSIS OF 
AEDES AEGYPTI SALIVARY GLAND TRANSCRIPTOME UPON INFECTION WITH 
DENGUE VIRUS  
 
2.1 Introduction 
 Dengue virus (DENV), the etiologic agent of dengue fever, is an enveloped, positive-
sense, single-stranded RNA virus of the genus Flavivirus.  DENV is maintained in a primarily 
anthroponotic cycle between humans and the Aedes aegypti mosquito [1].  Feeding by Ae. 
aegypti on vertebrate hosts involves the deposition of saliva, and thereby virus, into the skin [2-
5].  Mosquito saliva contains many proteins that modulate host hemostasis and immune 
responses, facilitating blood feeding and virus transmission [6, 7].  Ae. aegypti saliva also has 
been shown to contain allergenic proteins [8].  The vertebrate immune response to DENV 
infection is altered as a result of mosquito probing and the introduction of these immunogenic 
salivary proteins, thereby altering DENV infection kinetics and the likelihood of viral 
perpetuation [9].   
 As part of the investigation into the dynamics of the interface between mosquito, virus, 
and vertebrate, researchers have analyzed the composition of Ae. aegypti salivary glands at the 
transcriptional and protein expression levels [7, 10-16].  Work has been done to ascribe function 
to some of these salivary components and investigate their individual effects on vertebrate 
hemostasis and immune response, with many disrupting specific events in hemostasis (e.g., 
collagen-binding to platelets or vasoconstriction) or modulating the production of TH1 and TH2 
associated cytokines [10, 17-25].  Additional work into individual mosquito salivary proteins has 
shown that some serve as a boon to arboviral infection of the vertebrate, while other(s) may 
prove to be only a detriment [26-28].  Ae. aegypti saliva has been shown to also elicit protein-
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specific IgG and IgE responses in humans [16, 29].  The functionality of these individual 
salivary proteins in the context of establishment of a DENV infection in the vertebrate is an area 
that still requires thorough investigation. 
 Of particular importance are recent studies describing the effect that DENV serotype 2 
(DENV2) infection has on transcript and protein expression in the salivary glands or 
expectorated saliva of Ae. aegypti, each conducted with a different strain of virus and varying 
strains of mosquito.  One study using microarrays at the transcript level primarily demonstrated 
an increase in salivary gland transcript quantity upon DENV2, strain New Guinea C infection of 
Rockefeller strain mosquitoes [30].  In contrast, a high-throughput RNA-sequencing (RNA-seq) 
investigation primarily demonstrated a decrease in salivary gland transcript quantity upon 
DENV2, strain Jam1409 infection of Chetumal strain mosquitoes [31].  As a point of 
comparison, two studies utilizing two-dimensional gel electrophoresis at the protein level 
measured protein levels that are predominantly decreased or unaltered upon infection of 
Rockefeller strain mosquitoes with DENV2, strain 1232 [32, 33].  The disparity between these 
results indicates the need for an investigation into the strain-based influence of DENV infection 
on salivary gland gene expression in a unified setting. 
 As such, we examined the salivary gland transcriptome of female Ae. aegypti during 
infection with each of two strains of DENV2 in comparison to a sham-exposed control.  This 
investigation utilizes high-throughput RNA-seq analysis and is the first study to conduct a side-
by-side analysis of transcriptome modulation by multiple strains within one serotype.  The 
elucidation of strain-based differences, particularly in the abundance of expectorated salivary 
proteins, will provide a foundation from which to more accurately examine the interplay of 
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DENV and saliva during establishment of viral infection within the vertebrate host and how 
these interactions impact DENV perpetuation.  
 
2.2 Materials and Methods 
2.2.1 Viruses 
 DENV serotype 2 (DENV2) strains 1232 and 16803 were propagated as described 
previously [9]. Briefly, we inoculated T-75 flasks of confluent Vero cells with 100 µl of viral 
stock and incubated them for 30 min. Eight milliliters of M199E medium with 10% fetal bovine 
serum and 2% penicillin-streptomycin-amphotericin B (Fungizone) (P/S/F) was added. The flask 
was incubated at 37°C with 5% CO2 for 5 days, and subsequently the supernatant was collected 
for virus. The supernatants were found to contain 1.36 x 107 PFU/ml for 1232 and 2.61 x 107 for 
16803 by plaque assay as described previously in the supplemental material of reference [34], 
with modification. M199E medium containing P/S/F was used, and incubations occurred at 
37°C. 
 
2.2.2 Mosquito rearing and inoculation 
 Laboratory strain Ae. aegypti  (Rockefeller) were maintained in an environmental 
chamber at 28°C and 75 to 80% humidity and subjected to a 16:8 light-dark photoperiod regimen 
until the time of use. Mosquitoes were provided with a water and 10% sucrose solution ad 
libitum, which was removed 24 h prior to blood feeding and replaced thereafter.  Approximately 
one week post emergence, female mosquitoes were allowed to feed on bovine blood in Alsever’ 
s anticoagulant via Hemotek feeding device (Discovery Workshops, Lancashire, England), after 
which the blood-fed females were sorted. After 48 hours, these were then inoculated 
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intrathoracically with either DENV2 strain 1232 or strain 16803 as previously described [33]. 
The control group mosquitoes, also previously blood fed, received an inoculation of BA1 media 
(M199E, 10% bovine serum albumin, 0.1g/L L-glutamine, 2.2g/L sodium bicarbonate, 25mM 
HEPES, 2% P/S/F, titrated to 7.4 pH with Tris and HCl) without virus.   All mosquitoes were 
collected from the same rearing cohort to eliminate the influence of the potential variables of 
larval density, resource competition, and temperature or humidity fluctuations on salivary gene 
expression. 
 
2.2.3 Salivary gland collection and dissemination testing  
 After an 11-day extrinsic incubation period, mosquitoes were dissected, and their salivary 
glands were removed and stored individually at −80°C in 70 µl RLT buffer. Legs were removed 
and placed in 400 µl BA1 media for assessment of DENV positivity as a proxy for 
dissemination, as performed previously [32].  Legs were disrupted and homogenized using the 
TissueLyser (Qiagen, Valencia, CA) in accordance with the manufacturer’s instructions.  DENV 
RNA was extracted using the MagMax-96 Viral RNA Isolation Kit (Ambion/Life Technologies, 
Carlsbad, CA) and detected by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) assay with the Superscripts III® Platinum® One-Step qRT-PCR system (Life 
Technologies, Carlsbad, CA) on the LightCycler 480 (Roche Diagnostics Corp., Indianapolis, 
IN) and DENV concentration standards derived from plaque assays as previously described [26, 
35].  Only the salivary gland pairs from the mosquitoes with disseminated infections confirmed 
by qRT-PCR were combined to create a pool of infected salivary gland extract: 10 pairs pooled 
for each BA1 and 16803, 9 pairs pooled for 1232. 
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2.2.4 RNA processing and quality assessment for sequencing. 
 Upon confirmation of dissemination as above, the RLT solutions containing salivary 
gland pairs were pooled and then RNA was extracted using the RNeasy Tissue Mini kit (Qiagen, 
Valencia, CA).  A portion of this elution was then DNase I treated with the TURBO DNA-free™ 
Kit (Ambion/Life Technologies, Carlsbad, CA) and then processed with the NucleoTrap® 
mRNA Mini kit (Clontech Laboratories Inc., Mountain View, CA) to select for mRNA.   
 cDNA libraries were then constructed using the Ion Total RNA-Seq Kit v2 (Life 
Technologies, Carlsbad, CA) following the low input protocol to be analyzed in the Ion Proton 
System (Life Technologies, Carlsbad, CA).  Library quality was analyzed using the Agilent High 
Sensitivity DNA Kit on the 2100 Bioanalyzer Instrument (Agilent Technologies, Inc., Santa 
Clara, CA).  Average library size for the 1232 sample was found to be approximately 156 bp; for 
BA1 approximately 122 bp, and for 16803 approximately 133 bp.  Libraries were diluted to the 
11 pM concentration each (1232 was diluted 1: 570, BA1 was diluted 1:319, and 16803 was 
diluted 1:1500) and used for sequencing template preparation.  Template-positive Ion Sphere 
Particles (ISPs) containing clonally amplified DNA was produced using the Ion PI Template 
OT2 200 Kit v2 (for 200 base-read libraries) with the Ion OneTouch 2 instrument.  Ion 
OneTouch ES was used to enrich ISPs intended for Ion Proton System using the Ion PI 
Sequencing 200 Kit v2.  Individual Ion PI sequencing chips (no barcoding) were used for each of 
the sequencing samples.   
 
2.2.5 Data analysis 
 The Ae. aegypti reference genome assembly utilized for Ion Proton output alignment and 
further analysis is AaegL3, specifically the VectorBase scaffold file Aedes-aegypti-
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Liverpool_SCAFFOLDS_AaegL3.fa.  BAM files resulting from a standard Ion Proton 
processing and alignment of reads were uploaded to Galaxy (https://usegalaxy.org) [36-38].  A 
gene transfer format (GTF) file was generated for each BAM file using Cufflinks (Galaxy Tool 
Version 0.0.7) with a maximum intron length of 300000, minimum isoform fraction of 0.1, pre-
mRNA fraction of 0.15, effective length correction set to “yes,” and using the VectorBase 
reference annotation Aedes-aegypti-Liverpool_BASEFEATURES_AaegL3.1.gtf as guide [39].  
As the GTF file generated for strain 1232 repeatedly encounters an unknown error and returns as 
“empty,” only the GTF files for BA1 and strain 16803 were combined using Cuffmerge (Galaxy 
Tool Version 0.0.6) and the reference annotation utilized above [39].  Differential expression 
analysis was performed using Cuffdiff (Galaxy Tool Version 0.0.7) on these three BAM files 
with the merged GTF file, a geometric library normalization method, blind dispersion estimation 
method, a false discovery rate of 0.05, and a minimum alignment count of 10 [39].  Because the 
above samples are pooled, each pool only represents a statistical sample size of one and therefore 
the p value will be utilized as a guide rather than to strictly assess significance. 
 
2.2.6 RT-qPCR confirmation of transcript levels 
 The transcript levels of clade I and clade II aegyptins in the salivary gland pools above 
were analyzed using two-stage reverse transcription quantitative polymerase chain reaction on 
the LightCycler 480 (Roche Diagnostics Corp., Indianapolis, IN).  cDNA creation was 
performed using the SuperScript® III First-Strand Synthesis System (Life Technologies, 
Carlsbad, CA) following the random hexamer protocol.  qPCR was performed using the 
GoTaq® qPCR Master Mix (Promega, Madison, WI).  Cycling conditions were as follows: 95°C 
for 5 min followed by 40 cycles of 95°C for 10 s, 58°C for 20 s, and 72°C for 20 s.  Resultant 
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crossing point (Cp) values were compared using the ΔΔCp method [40, 41]. The normalization 
gene used for this method was 40S ribosomal protein S5 (RPS5).  Primer sequences are listed in 
Table 2.1. 
 
Table 2.1: Primer sequences for RT-qPCR confirmation of high-throughout sequencing results. 
 
Gene ID Forward (5’-3’) Reverse (5’-3’) 
AAEL010228  
(clade I aegyptin) 
CTT AGG TGT TCG CTA CAT 
TAT GAA AT 
CGT GAG CAT TAA GTT CAC 
TAG GC 
AAEL010235 
(clade II aegyptin) 
GAA GGT GAA GAA CAT GCT 
GGA 
 
CAG CAT CGT CAT GTC CTG 
TAT T 
AAEL013625 
(RPS5) 
CGT CGT GTC AAC CAG GCT 
A 
 
GTT ACG GAA TGC AGC TTC 
G 
 
 
 
2.3 Results 
2.3.1 Ion Proton General Output 
 Using the Ion Proton high-throughput sequencer for RNA-seq analysis, we analyzed the 
transcript levels of pooled salivary glands of female Ae. aegypti mosquitoes.  These salivary 
glands were infected with DENV2 strain 1232 or strain 16803, or were uninfected (BA1 media-
inoculated) controls.  A total of 61,831,241 reads were generated for the 1232 sample with total 
output of 7.4 G.  A total sequence output of Q20 quality that is derived from the predicted per-
base quality scores and corresponds to an error rate of 1% generated approximately 4.1x 
coverage of the reference genome.  A total of 41,395,724 reads were generated for the 16803 
sample with total output of 4.7 G.  A total sequence output of Q20 quality generated 
approximately 2.3x coverage of the reference genome.  A total of 54,753,501 reads were 
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generated for the BA1 sample with total output of 6.1 G.  A total sequence output of Q20 quality 
generated approximately 2.5x coverage of the reference genome.   
 
2.3.2 Differential transcript levels 
 There were a total of 236,181 comparisons generated, with 78,727 unique test IDs, and 
74,736 unique gene loci (including four mitochondrial loci).  Of these, 49,974 were differential 
comparisons (p≤0.05).  There were 22,362 loci with differential transcript levels between strain 
16803 and BA1, of which 288 had fragments per kilobase of exon per million fragments mapped 
(FPKM) values ≥1 in both data sets.  There were 17,865 loci with differential transcript levels 
between strain 1232 and BA1, of which 232 had FPKM values ≥1 in both data sets.  There were 
9,747 loci with differential transcript levels between strains 16803 and 1232, of which 166 had 
FPKM values ≥1 in both sample sets. 
 Of particular interest were the proteins previously identified with differential abundance 
in the expectorated saliva of Ae. aegypti with disseminated DENV2 strain 1232 infections [33].  
The amino acid sequences of these proteins were compared to the VectorBase database using 
BLAST to obtain the VectorBase designations that likely correspond.  The remainder of this 
investigation will focus on said proteins, as well as other expectorated salivary proteins of 
putative importance in the literature.  The aforementioned expectorated proteins, their FPKM 
values, and any differential transcript levels are displayed in Table 2.2.  Other expectorated 
proteins, as well as putatively secreted proteins and related proteins, their FPKM values, and any 
differential transcript levels are displayed in Table 2.3. 
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2.3.3 Confirmation of high-throughput sequencing results 
 We set out to confirm the differential transcript levels for clade I and clade II aegyptins 
observed in the high-throughput sequencing output by utilizing a more traditional RT-qPCR 
assay.  In DENV2 strain 1232 infected salivary glands relative to BA1 control, clade I aegyptin 
transcript was detected in 19.97-fold greater quantities and clade II aegyptin transcript was 
detected in 6.28-fold greater quantities.  These transcript levels reflect the directionality and 
relative magnitude of change observed in the sequencing FPKM data, but to a greater degree 
(Figure 2.1). 
 
 
Figure 2.1: Confirmation of differential transcript levels of clade I and clade II aegyptins 
between DENV2 strain 1232 infected salivary glands and BA1 control salivary glands by qRT-
PCR.
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Table 2.2: Expectorated salivary proteins of Ae. aegypti.  Gene IDs listed here were obtained by BLAST into VectorBase using 
peptide sequences from a previous publication [33]. † = significantly different protein abundance between strain 1232 and media 
control in previous publication. * = p ≤ 0.05 in current investigation. 	  
VectorBase 
Gene ID Description 
strain 
1232 
FPKM 
strain 
16803 
FPKM 
control 
BA1 
FPKM 
1232 
vs. 
BA1 
16803 
vs. 
BA1 
1232 
vs. 
16803 
AAEL000533 C-Type Lectin 503 1218 323 --- * --- 
AAEL000732† conserved hypothetical protein 208 252 55 * * --- 
AAEL000793 Venom allergen 1694 2884 576 --- * --- 
AAEL002704† Serine Protease Inhibitor (serpin) homologue 9321 920 181 * * --- 
AAEL003600 conserved hypothetical protein (putative 34kD family secreted salivary protein) 965 904 449 --- --- --- 
AAEL005672† adenosine deaminase 390 1103 76 * * --- 
AAEL006347 Apyrase precursor (Allergen Aed a 1) 1166 2280 272 * * --- 
AAEL006417 D7 protein, putative 3380 6033 571 * * --- 
AAEL006424 37 kDa salivary gland allergen Aed a 2 Precursor (Protein D7)(Allergen Aed a 2) 1904 1904 344 * * --- 
AAEL007041† Low-density lipoprotein receptor (ldl) 0.58 1.14 3.14 --- --- --- 
AAEL008463 DEAD box ATP-dependent RNA helicase 2 0.47 0.09 --- --- --- 
AAEL010228† 
conserved hypothetical protein (short-form 
aegyptin; SAAG-4; clade I aegyptin) 2150 530 229 * --- * 
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Table 2.3: Expectorated salivary proteins and related or putatively secreted proteins of Ae. aegypti. * = p ≤ 0.05. 
VectorBase 
Gene ID Description 
strain 
1232 
FPKM 
strain 
16803 
FPKM 
control 
BA1 
FPKM 
1232 
vs. 
BA1 
16803 
vs. 
BA1 
1232 
vs. 
16803 
AAEL000028 Clip-Domain Serine Protease family B 17 88 10 --- * --- 
AAEL000229 
Prosialokinin Precursor {Contains 
Sialokinin(Sialokinin-1)(Sialokinin I)(Sia 
I)(Sialokinin-2)(Sialokinin II)(Sia II)} 
1815 810 323 * --- --- 
AAEL000556 C-Type Lectin 390 977 26 * * --- 
AAEL001098 clip-domain serine protease, putative 99 40 187 --- * --- 
AAEL002610 serine protease 96 20 18 * --- --- 
AAEL003057 allergen, putative 474 1011 34 * * --- 
AAEL003182 Serine Protease Inhibitor (serpin) homologue – unlikely to be inhibitory 330 370 55 * * --- 
AAEL005641 C-Type Lectin (CTL) - galactose binding. 78 16 49 --- --- * 
AAEL005997 allergen, putative 123 20 58 --- --- * 
AAEL006333 salivary apyrase, putative 100 275 32 --- * --- 
AAEL007420 Serine Protease Inhibitor (serpin) homologue – unlikely to be inhibitory 71 191 13 --- * --- 
AAEL008620 D7 protein, putative 27 43 6 --- * --- 
AAEL010235 
30 kDa salivary gland allergen Aed a 3 Precursor 
(Allergen Aed a 3; clade II aegyptin) 7233 1530 1573 * --- * 
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2.4 Discussion 
 The differential changes in transcript levels among salivary glands infected with DENV2 
strain 1232 or strain 16803 as compared to those of control, BA1 media-inoculated female Ae. 
aegypti suggest the potential for saliva to play a role in strain-based differences in viral 
perpetuation success.  For example, co-exposure of strain 1232 and the salivary proteins aegyptin 
(clade II; AAEL010235) or C-type lectin (AAEL000533) are shown in chapter 4 of this 
dissertation to have a detrimental effect on DENV production in a human hematopoietic cell line 
when compared to DENV-only exposure.  Additionally, co-exposure of strain 1232 and aegyptin 
(clade II) led to alterations in cytokine production, inoculation site titers, and viremia titers in 
mice when compared to DENV-only exposure, as outlined in chapter 5 [26].  As displayed in 
Tables 2.2 and 2.3 above, infection with strain 16803 led to much greater changes in C-type 
lectin transcript level (3.77x) and essentially no change in the level of aegyptin (clade II; 0.97x) 
transcript relative to BA1 media control, when compared to the modulation elicited by infection 
with strain 1232 (1.56x and 4.60x, respectively).  Additionally, a previous study found that 
infection with DENV2 strain Jam1409 resulted in no change to the level of clade II aegyptin, 
whereas the level of clade I aegyptin (AAEL010228) was more than 2x different from control 
levels (in comparison to the 9.39x and 2.31x differences seen here for strains 1232 and 16803, 
respectively) [31].  The salivary protein profiles of Ae. aegypti mosquitoes may be differentially 
pressured by the various strains of DENV2 as a compensation mechanism for differences in viral 
fitness. 
 Accordingly, it has been shown previously that these two strains of DENV2 exhibit 
differences in infection kinetics in the vertebrate and efficiency in the vector [35, 42].  With 
regard to the vertebrate infection kinetics, infection with DENV2 strain 1232 elicited a longer 
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viremia (four days versus two) with significantly greater magnitude than did strain 16803 (Figure 
2.2).  Additionally, strain 16803 elicited significantly greater concentration of IFNγ when 
compared to strain 1232 (Figure 2.3), among other cytokine alterations [42].  With regard to 
efficiency in the vector, strain 1232 had a higher dissemination rate (0.35) compared to strain 
16803 (0.06) on day seven post exposure in female Ae. aegypti, and strain 16803 then surpassed 
the dissemination rate of strain 1232 on day 9 post exposure (0.58 and 0.44, respectively) [35].  
The existence of these strain-based phenotypic differences and the relatively poor success of 
strain 16803 in the vertebrate (without the influence of saliva) lend credence to a differential 
reliance on salivary proteins for viral perpetuation. 
 
 
 
Figure 2.2: Mean viremia levels of DENV infections by different strains from interferon 
regulatory factor 3 & 7 double knock-out mice. Mean viremia levels are aligned by day of peak 
viremia (P0).  Figure reproduced with permission from the authors. 
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Figure 2.3: IFNγ response of DENV infections by different strains from interferon regulatory 
factor 3 & 7 double knock-out mice.   Mean concentrations are aligned by day of peak viremia 
(P0).  Figure reproduced with permission from the authors. 
 
 
 Importantly, the transcript levels of some salivary proteins were altered to similar degrees 
by both strains of DENV2, and some were not substantially altered from control values.  An 
example of a protein whose transcript level was altered similarly by both strains is the D7 protein 
allergen Aed a 2 (AAEL006424).  The two strains elicited identical FPKM values herein for the 
transcript of this protein, and were 5.53x greater than BA1 media control.  Further, a previous 
investigation demonstrated that immunization of mice with a D7 protein from Culex tarsalis 
significantly increased neurovirulence of West Nile virus when exposed by infectious mosquito.  
The potential necessity to maintain at least a certain level of some proteins is exemplified by the 
lesser degree of difference between infected pools, and the relative similarity of their FPKM 
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values to those of control samples, in the transcript levels of the putative 34kDa family member 
protein (AAEL003600) measured herein and its effect on DENV infection observed previously.  
This protein has been shown to significantly decrease the production of IFNα and IFNβ 
transcript levels, as well as that of the transcription factors IRF-3 and -7, and the antimicrobial 
peptides LL-37, S100A7, and RNase7 in DENV-infected human keratinocytes.  These 
modulations were concurrent with a significant increase in the concentration of DENV genomic 
RNA [27].  The nature of these transcript levels and others speaks to the potential commonality 
of importance (or a lack thereof) of certain salivary proteins in the perpetuation of DENV.  
 The variety of differential, salivary protein transcript levels observed in this study among 
the two DENV2 strains and the control, as well as the potential impact of these differences on 
DENV infection of the vertebrate, speak to a dynamic nature of the interaction between DENV 
strains, the mosquito vector, and the vertebrate in DENV perpetuation.  However, it is important 
to note here that transcript levels are not always an accurate depiction of protein levels.  This is 
evident in Table 2.2, where clade I aegyptin (AAEL010228) was observed with dramatically 
increased transcript levels upon infection with strain 1232, whereas the aforementioned previous 
publication found the expectorated protein levels to be significantly reduced upon infection with 
this DENV strain at a similar time point post inoculation [33].  Therefore, further work into the 
strain-based protein profiles of expectorated saliva, the mechanism underlying the disparity 
between transcript accumulation and protein production, and the impact of differing salivary 
protein profiles on DENV transmission and pathogenesis are warranted. 
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CHAPTER 3 
ANALYSIS OF EARLY DENGUE VIRAL INFECTION IN MICE AS MODULATED BY 
AEDES AEGYPTI PROBING1 
 
3.1 Introduction 
 Dengue virus (DENV), the etiologic agent of dengue fever, is an enveloped, positive-
sense, single-stranded RNA virus of the genus Flavivirus.  DENV prevalence has increased in 
recent decades and now infects an estimated 50-100 million humans world wide annually of 
approximately 2.5 billion at risk for infection [1].  The increased risk for infection can be 
attributed, in part, to the continued growth and urbanization of human populations and an 
expanded global distribution of the primary vectors of DENV: the mosquitoes Aedes aegypti and 
Ae. albopictus [2].   Feeding by these vectors on vertebrate hosts is initiated by probing that 
results in physical damage to the epithelium and vasculature, as well as the simultaneous 
introduction of virus and saliva into host tissues [3-6].  This saliva contains many 
pharmacologically important proteins that modulate host haemostasis and innate immune 
responses, which in turn facilitate blood feeding and virus transmission [7-9].  As exogenous 
antigen, both salivary proteins as well as virus encounter the vertebrate host immune system and 
consequently could have an effect on the environment of the bite site during viral establishment.   
 To investigate the impact of the vector on mosquito-borne viral infection, researchers 
have analyzed viral titers and/or immunological response markers utilizing various methods of 
mosquito involvement, including salivary gland extract (SGE) [10-16], infected mosquitoes [14, 
17-23], and spot-feeding [11, 12, 14, 24].  The immunological effects of mosquito saliva and/or 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1This chapter previously appeared as McCracken M K, Christofferson R C, Chisenhall D M, and 
Mores C N. 2014. Analysis of Early Dengue Virus Infection in Mice as Modulated by Aedes 
aegypti Probing. J Virol 88:1881-1889.  It is reprinted by permission of American Society for 
Microbiology. 
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probing in these arboviral infection experiments were examined at time points of 24 hours post 
exposure or later, with three notable exceptions.  Limesand et al. assayed IFN α/β expression 
four to 48 hours post exposure in response to vesicular stomatitis virus infection in vitro, 
following treatment with SGE [10]; Thangamani et al. assessed the response to chikungunya-
infected Ae. aegypti mosquito bites in mice at three and six hours post exposure [22]; and 
Surasombatpattana et al. examined the effect of Ae. aegypti SGE on DENV infection in human 
keratinocytes in vitro at six and 24 hours post exposure [15].  Three other studies have 
investigated the effects of Aedes saliva on DENV infection of the vertebrate host [17, 25, 26], 
with observations again gathered 24 hours post exposure or later.   
 The immunological modulations observed in these DENV studies would likely affect the 
progression of DENV infection and disease.  However, the time points utilized are distinctly 
separate from the act of transmission or time of inoculation and therefore may not describe the 
events that occur in vivo during the early hours of DENV infection.  The investigation of 
potential differences at earlier time points will clarify the acute dynamics of DENV transmission 
at the bite site in the context of mosquito probing and expectorated saliva.  As such, we 
examined the early in vivo transcriptional changes of murine innate immune recognition and 
response pathways at sites of DENV inoculation due to contemporaneous Ae. aegypti probing.   
 Specifically, we assessed potential differences in the murine Toll-like receptor (TLR), 
nod-like receptor (NLR), and RIG-I-like receptor (RLR) signaling pathways between skin 
samples that had or had not been probed by mosquitoes immediately prior to DENV inoculation.  
TLRs, NLRs, and RLRs are pattern recognition receptors critical to the detection of viral 
pathogens by the innate immune system.  The subsequent signaling pathways initiate a cascade 
of events that include activation and nuclear translocation of transcription factors, increased 
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transcription of antiviral genes, and the production of effector proteins with the ultimate goal of 
creating an antiviral immune environment.  We utilized commercial qPCR-based transcript 
arrays of 84 genes each as broad screens for differential gene expression in these pathways at 3 
hours post inoculation.  Following these arrays, we assayed transcript of four differentially 
expressed genes and two housekeeping genes using gene-specific primer sets at 10 minutes, 3 
hours, and 6 hours post inoculation.  The four differentially expressed genes assayed were Toll-
like receptor 7 (TLR7), v-rel reticuloendotheliosis viral oncogene homolog A (avian) / 
transcription factor p65 (RelA), interferon (IFN)-γ, and interferon-γ-inducible protein 10 / 
CXCL10 (IP-10).  The two housekeeping genes assayed were glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and the ribosomal protein L-32.  Taken together, the differential 
regulation of these transcripts, as modulated by mosquito probing, informs on a vertebrate host 
environment that may benefit the establishment of DENV immediately following transmission. 
 
3.2 Materials and Methods 
 All experiments met the approval and conditions of the LSU Institutional Animal Care 
and Use Committee (protocol # 12-079).  LSU IACUC procedures and policies adhere to and 
comply with the guidelines stated in the NIH Guide for the Care and Use of Laboratory Animals. 
 
3.2.1 Mosquitoes  
 Mosquitoes utilized in this study are field-caught Aedes aegypti from New Orleans, LA 
generously provided by City of New Orleans Mosquito, Termite, & Rodent Control Board and 
by Dawn Wesson (Tulane University School of Public Health and Tropical Medicine, New 
Orleans, LA).  Mosquitoes were maintained in an environmental chamber at 28°C, 75–80% 
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humidity, and subjected to a 16:8 light:dark photoperiod regime until time of use.  Mosquitoes 
were provided with water and 10% sucrose solution ad libitum, which was removed 24 hours 
prior to experimentation. 
3.2.2 Mice 
 Mice were the generous gift of Dr. M. Diamond (Washington University, St. Louis, MO) 
with permission from Dr. T. Taniguchi (University of Tokyo, Tokyo, Japan).  These IRF-3/7 -/- -/- 
mice are on a C57Bl/6 background and lack functional IRF 3 and 7, and as such have a deficient, 
but not abrogated, type I IFN response. [27].  These mice have been demonstrated previously to 
be a suitable model for DENV transmission by both mosquito and needle inoculation, with 
cytokine responses, DENV replication, and resulting viremia evaluated [28]. 
 
3.2.3 Virus 
 Dengue serotype 2, strain 1232 was propagated as described previously [29], with 
modification.  Briefly, we inoculated a T-75 flask of confluent Vero cells with 100 µl of viral 
stock and incubated for 30 minutes.  Eight mL of M199E medium with 10% fetal bovine serum 
and 2% penicillin / streptomycin / fungizone (P/S/F) was added.  The flask was incubated at 
37°C with 5% CO2 for 5 days and subsequently the supernatant was collected for virus at peak 
titer.  The supernatant was titered to contain 6.7x106 PFU/mL using a plaque assay as described 
previously in [30] supplemental material, with modification.  M199E medium containing P/S/F 
was used and incubations occurred at 37°C.  This strain was originally isolated from a patient in 
Indonesia in 1978 (personal communication, R. Tesh), and examined previously in mice [28].  
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3.2.4 Exposure & sample collection 
 Three Aedes aegypti females were allowed to feed on the pinna of one restricted ear of 
each mouse for 10 minutes from initiation of probing.  Mice then immediately received 
intradermal needle-inoculation (10uL) of 6.7x104  PFU of DENV in the location of mosquito 
probing and in a similar location in the opposite ear.  Thus, both the treatment group – the one 
ear where mosquitoes had probed – and the control group – the ear where mosquitoes had not 
probed – were located on the same mouse in order to control for mouse-to-mouse variation.  At 
10 minutes (n=10), 3 hours (n=8), and 6 hours (n=10) post inoculation, mice were CO2 
euthanized, then the pinnae of their ears were removed and homogenized.  Subsequently, RNA 
was purified and cDNA then created for each sample.  A separate group of mouse ears exposed 
only to mosquito probing were collected at these same time points (7, 6, and 7 ears respectively).  
Ten additional, unexposed mouse ears were collected for comparison. 
 Two groups of four additional mice were exposed as above to DENV with and without 
mosquito probing.  These mice were bled via submandibular vein puncture daily for the next six 
days.  This blood was collected in microcentrifuge tubes, allowed to clot for thirty minutes at 
room temperature, and then centrifuged at 8000 rcf for four minutes at 4°C.  Clarified serum was 
placed into clean microcentrifuge tubes and stored at -80°C until nucleic acid extraction and 
subsequent measurement of viremia.   
 
3.2.5 RNA purification and cDNA creation 
 Individual mouse ears were disrupted and homogenized in 600ul RLT + β-ME buffer 
using the TissueLyser (QIAGEN, Valencia, CA) as per manufacturer’s instructions.  RNA was 
then purified using the RNeasy Fibrous Tissue Mini Kit (QIAGEN, Valencia, CA) with on 
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column DNase I treatment (QIAGEN, Valencia, CA).  Total nucleic acid was extracted from 
clarified mouse serum using the MagMax-96 Total Nucleic Acid isolation kit (Ambion/Life 
Technologies, Carlsbad, CA). 
 A uniform quantity of total RNA per mouse ear, as determined by NanoDrop ND-1000 
(Thermo Fisher Scientific, Wilmington, DE) A260 reading, was used for each pair of ears to 
create cDNA.  cDNA creation was performed using the RT2 First Strand Kit (SABiosciences, 
QIAGEN, Valencia, CA) for the RT2 Profiler PCR Arrays or the SuperScript® First-Strand 
Synthesis System for RT-PCR (Life Technologies, Carlsbad, CA) with oligo-dT primer for 
follow-up testing. 
 
3.2.6 Viral titer assessment 
 RNA was extracted from all ear tissue and serum samples as described above.  Titers of 
DENV were measured by qRT-PCR assay using the One-Step TaqMan qRT-PCR system (Life 
Technologies, Carlsbad, CA) and DENV concentration standards derived from plaque assays, as 
previously described [29].  As such, viral titers are expressed as PFU-equivalents/mL, 
symbolized as PFU*/mL. 
 
3.2.7 Transcript assays  
 All samples were tested using real-time quantitative PCR (qPCR) on the Roche 
LightCycler480 in 384-well format.   
 The first assays performed used the TLR (PAMM-018A) and Antiviral (PAMM-122Z) 
RT2 Profiler PCR Arrays (SABiosciences, QIAGEN, Valencia, CA) as low-replicate screens of 
some 3 hours post inoculation samples for TLR and antiviral responses in the mouse.  These 
	   58	  
commercial plate arrays assay the expression of 84 different genes along various innate immune 
pathways as well as housekeeping genes and quality controls.  Samples were prepared according 
to manufacturer’s instructions. 
 Follow-up testing of all samples was conducted with individual primer sets (Integrated 
DNA Technologies, Coralville, IA) for TLR7, IFN-γ, IP-10, RelA, L-32, and GAPDH using 
EXPRESS SYBR GreenER qPCR SuperMix Universal (Life Technologies, Carlsbad, CA).  
Primer sequences are shown in table 3.1.  Samples were assayed in triplicate using 10ul reaction 
volumes and a cDNA concentration per reaction equivalent to 3.34ng starting total RNA (to 
equilibrate cDNA loads to the RT2 Profiler PCR Arrays).  The run parameters were as follows: 
95°C for 5 minutes followed by 40 cycles of 95°C for 10 seconds, 58°C for 20 seconds, 72°C for 
20 seconds. 
 
 Table 3.1:  Primer sequences listed 5’-3’, source publications, and NCBI reference genes. 
*Modified from original sequence publication 
 
 
Gene NCBI Gene: # Forward Primer Reverse Primer Source 
TLR7 Tlr7: 170743 GGC ATT CCC ACT AAC 
ACC AC 
TTG GAC CCC AGT AGA 
ACA GG 
[31] 
GAPDH Gapdh: 14433 TGC ACC ACC AAC TGC 
TTA GC 
TGG ATG CAG GGA TGA 
TGT TC 
[31] 
IP-10 Cxcl10: 15945 CAG TGA GAA TGA GGG 
CCA TAG G 
CTC AAC ACG TGG GCA 
GGA T 
[31] 
IFN-y Ifng: 15978 CCA TCG GCT GAC CTA 
GAG AA 
ATG AGG AAG AGC TGC 
AAA GC 
[32] 
RelA Rela: 19697 CTT CTG GGC CTT ATG 
TGG AGA T 
TCG CAT TTA TAG CGG 
AAT CG 
  [33]* 
L-32 Rpl32: 19951 TAA GCG AAA CTG GCG 
GAA ACC 
AGG ATC TGG CCC TTG 
AAC CT 
  [33]* 
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3.2.8 Analysis  
 The ΔΔCp method [34, 35] was used in order to calculate fold-change and fold-regulation 
differences between the treatment and control groups.  The ΔΔCp method is discussed here 
briefly.  The average Cp for all qPCR technical replicates is calculated first.  For our study, this 
was done on a per ear basis (Equation 1).  Next, the ΔCp is calculated, which is the Cp value for 
the gene of interest minus the Cp value for the designated housekeeping gene, again on a per ear 
basis (Equation 2).  To get the ΔΔCp, the control ΔCp is subtracted from the treatment ΔCp.  For 
our study, this was done by subtracting the control ear ΔCp from the treatment ear ΔCp, on a per 
mouse basis (Equation 3).  Fold-change values are then equal to 2 raised to the negative ΔΔCp 
(Equation 4). 
 
Equation 1: CpAvg = (Cp1 + Cp2 + … + Cpn)/n, per ear 
Equation 2: ΔCpAvg = CpAvgGOI – CpAvgHKG, per ear 
Equation 3: ΔΔCp = ΔCpAvgTRT – ΔCpAvgCTRL, per mouse 
Equation 4: Fold-change = 2(−ΔΔCp), per mouse 
 
 Since a fold-change value of 1 indicates that the values between the treatment and control 
groups did not change, any fold-change value greater than one is an increase in the amount of 
transcript produced.  Similarly, a fold-change value less than one indicates a decrease in the 
amount of transcript produced.  Fold-regulation is a manipulation that allows for better 
conceptualization of the data.  This adjusts the relative scale of the data such that a 2-fold 
increase and a 2-fold decrease would have the same absolute value, making zero on the y-axis 
the turning point between the directionality of change, rather than one (Equation 5 & 6). 
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Equation 5: Fold-regulation = fold-change, for values ≥1 
Equation 6: Fold-regulation = − (1/fold-change), for values <1 
 
 Statistical analysis was then performed on fold-change values using SAS 9.2 (Cary, NC).  
Student’s t-test was utilized with a null hypothesis of the mean of the differences between 
control and treatment ears equal to 1.  Significance was assessed at, and confidence intervals of 
the differences were calculated based on, an α value of 0.05.  Differences in viral titers between 
treatments at each time point were compared using a one-way ANOVA with repeated measures 
to control for intra-mouse variation on the two treatment categories. For the serially bled mice, a 
one-way ANOVA was performed per day post exposure, but without repeated measures.  Again, 
significance was assessed at an α value of 0.05. 
 
3.3 Results 
3.3.1 DENV titers 
 Based on the qRT-PCR assay, the titer of DENV in ears of mice that received mosquito 
probing were not found to differ significantly (p>0.05) from DENV titers in ears that received 
DENV injection alone at 10 minutes, 3 hours, and 6 hours post inoculation (Figure 3.1).  
However, mice that received mosquito probing demonstrated a significantly greater viremia titer 
on days 3 and 4 post exposure.  In addition, DENV RNA was detectable through day 6 post 
exposure in the mosquito probing group, whereas DENV RNA was evident in only one mouse 
on day 5 and undetectable on day 6 post exposure in the virus only group (Figure 3.2). 
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Figure 3.1: DENV titers in ear samples at 10 minutes, 3 hours, and 6 hours post inoculation.  
DENV titers, expressed as PFU-equivalents/mL (PFU*/mL), did not differ significantly between 
samples exposed to mosquito probing and those injected with DENV alone (p>0.05). 
 
3.3.2 Preliminary transcript arrays  
 Based on the SABiosciences RT2 Profiler PCR Arrays, there was differential regulation 
of many genes for innate immune receptors including TLR 7, Ifih1/MDA5, and Nod2; the MAP 
kinases; activators, inhibitors, and adaptors of signaling such as Ticam1 and Nfkbia; 
transcription factors such as the subunits of NF-κB, Rel and RelA; enzymes such as caspase 1; 
and cytokines including IFN-γ and IP-10 (data shown in supplement).  In the Ae. aegypti spot-
feeding treatment group relative to the virus only control group, the differential expression 
observed for the transcripts of TLR7 (3.88x down-regulated), RelA (3.4x up-regulated), IFN-γ 
(6.13x down-regulated), and IP-10 (2.86x down-regulated) was chosen for further study.  In 
total, 41 transcripts were at least 2-fold down-regulated and 12 transcripts were at least 2-fold 
up-regulated out of a total 130 targets (Figure 3.3). 
 
	   62	  
Figure 3.2: DENV viremia titers in serum samples on the first six days post exposure.  DENV 
titers, expressed as PFU-equivalents/mL (PFU*/mL), were significantly higher in mice exposed 
to mosquito probing + virus compared to those that received only DENV inoculation on days 3 
and 4 post exposure, as indicated by asterisks (p<0.05).  Associated bars represent standard error 
of the means. 
 
 During this initial investigation, we observed that the housekeeping genes normally used 
in these transcript arrays (e.g. GAPDH) had a more variable response between the two treatments 
than we thought appropriate for a standardizing method.  In some cases, subsequent assays 
revealed this Cp difference to be indicative of over a log-fold difference in GAPDH expression.   
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Figure 3.3: Preliminary transcript arrays.  Differential regulation of genes for transcription 
factors, innate immune receptors, the MAP kinases, enzymes, cytokines, chemokines, and 
activators, inhibitors, and adaptors of signaling was detected in mouse ear samples that received 
mosquito probing + DENV2 inoculation relative to DENV2 inoculation alone.  A cutoff of 2-
fold up- or down-regulated was used to assess which genes were differentially expressed 
(colored bars surpass the grey 2-fold cutoff).  The transcripts of RelA (3.4x up-regulated), TLR7 
(3.88x down-regulated), IFN-γ (6.13x down-regulated), and IP-10 (2.86x down-regulated) are 
marked in their respective categories.  Forty-one transcripts (31.5%) were at least 2-fold down-
regulated and 12 transcripts (9.2%) were at least 2-fold up-regulated out of a total 130 targets.  
The colors of each category correspond to the similarly colored sections in the data supplement.
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Thus, we assessed other housekeeping genes and determined L-32 was the most stable, and as 
such was used as the housekeeping gene for the remainder of the study (Figure 3.4). 
 
 
 
Figure 3.4:  qPCR amplification curves representing GAPDH and L-32 fluorescence and Cp 
values for a set of treatment and control samples.  Arrows represent the approximate cycle where 
amplification curves cross the threshold. 
 
3.3.3 Subsequent targeting of transcripts  
 We then used individual primer sets to specifically target the four genes outlined above, 
as well as our chosen housekeeping gene, L-32.   Once the ΔΔCp were calculated, we observed 
significant transcript down-regulation of all four of our genes of interest for the spot-feeding 
treatment group relative to the virus only control group at 3 hours post inoculation.  The fold- 
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regulation values for these transcripts were calculated to be as follows: TLR7 = -2.33x 
(p=0.008), RelA = -2.59x (p=0.001), IP-10= -2.75x (p=0.004), IFN-γ = -2.17x (p=0.036).  These 
values and the associated 95% confidence intervals are shown in figure 3.5. 
 When the study window was expanded out to 6 hours post inoculation, we observed no 
difference in fold-change values relative to 1, indicating a convergence in expression of the two 
groups by this time point.  We then looked at expression 10 minutes post completion of viral 
inoculation.  Shown in figure 3.5, this cohort exhibits a great deal of variation in the expression 
levels of the two groups.  While there may be a trend toward up-regulation at this time point, 
only IFN-γ shows significant up-regulation (3.04x, p=0.034). 
  
 
Figure 3.5:  Fold-change values for each of the four genes of interest at 10 minutes, 3 hours, and 
6 hours post inoculation in mouse ear samples that received mosquito probing + DENV2 
inoculation relative to DENV2 inoculation alone.  Asterisks represent significance of fold-
change values as different from 1 (p<0.05).  Associated bars represent 95% confidence intervals 
for each gene per time point, thus bars that do not overlap 1 indicate significance. 
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 Additionally, the relative abundance of expression in all samples (mosquito + virus, virus 
only, mosquito only, and unexposed ears) was calculated for each gene of interest relative to the 
normalization gene L-32, shown in figure 3.6.  The expression level of each gene in unexposed 
ears tended to be lower than the other three groups, while the expression level of the mosquito 
only group in relation to the virus only and mosquito + virus groups varies depending on the 
gene. 
 
3.4 Discussion 
 The preliminary immune pathway transcript arrays revealed 31.5% of target transcripts 
were at least 2-fold down-regulated whereas only 9.2% of transcripts were at least 2-fold up-
regulated.  Importantly, 11 of the down-regulated transcripts were receptors and 9 were 
proinflammatory cytokines and chemokines.  The down-regulation of these transcripts suggests a 
propensity for mosquito-induced, generalized suppression of the inflammatory response and a 
reduction in infiltrating leukocytes.   
 The transcripts for TLR7, RelA/p65, IFN-γ, and IP-10/CXCL10 were examined 
individually due to the changes in expression observed in our preliminary transcript arrays and 
the potential for these genes to affect dengue viral establishment.  Plasmacytoid dendritic cells 
expressed increased levels of the ssRNA receptor TLR7 in response to DENV exposure and 
recognize DENV genomic RNA in a replication-independent manner, resulting in production of 
type I interferon that was inversely proportional to DENV titer [36].  Additionally, PBMCs from 
clinical patients in Thailand exhibited down-regulation of TLR7 in secondary DHF cases [37].  
RelA is part of the NF-κB complex and is responsible for the induction of many inflammatory 
cytokines, as well as DENV-induced expression of MHC class I [38] and early production of
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Figure 3.6: Relative abundance of expression for each gene of interest normalized to L32 
expression in mouse ears.  The groups depicted are unexposed, mosquito probing only, virus 
inoculation only, and virus inoculation + mosquito probing at 10 minutes, 3 hours, and 6 hours 
post inoculation.  Values depicted represent mean relative abundance and associated bars 
represent the standard deviation. 
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IFN-β, leading to resistance to RNA viral replication [39].  IFN-γ has manifold effects, including 
enhanced activation of DENV-infected dendritic cells [40] and, in combination with IFN-β, 
inhibition of DENV RNA translation[41].  The vital importance of IFN-γ is further exemplified 
by one of the primary mouse models for DENV infection, the AG129 mouse, which lacks a 
functional IFN-γ response and thereby suffers clinical illness and increased DENV titers [42].  
IP-10 is an antigen-presenting cell chemokine induced by IFN-γ that was also shown to 
competitively inhibit DENV attachment to new cells, resulting in decreased DENV titer [43].  
Similarly, an approximately two-fold decrease in average IP-10 concentration was demonstrated 
to increase the DENV titer in monocyte-derived dendritic cells [44].  As potential internal 
controls for normalization we also measured GAPDH and L-32 transcript levels.  GAPDH is a 
traditional housekeeping gene involved in the glycolysis cycle.  L-32 is a component of the 60S 
ribosomal RNA subunit and a less traditionally used transcription control.   
 In reference to the choice of L-32 as our housekeeping gene for the individual transcript 
assays (as opposed to those as used in the preliminary transcript arrays), it is important to note 
that in addition to the variation in GAPDH expression we observed between the treatment and 
control groups, the literature indicates that increased GAPDH expression is often observed in 
studies of cellular activation and stress-induced apoptosis [45, 46].  There is also literature 
stating that certain viral infections, such as Newcastle disease, influenza, and vaccinia viruses, 
can modulate GAPDH expression [47-49].  As such, we opted to use the more stably expressed 
L-32 as the gene of reference for data normalization, and suggest that this gene is a better choice 
for future transcript studies involving DENV and mosquito feeding. 
 This study provides the first transcriptional analysis of the effects of mosquito probing on 
the in vivo immune response to DENV infection at time points prior to 24 hours post exposure.  
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In 2010, Thangamani et al. worked to assess the immune response to early chikungunya virus 
infection by measuring transcript levels at 3 and 6 hours post inoculation.  Notably, they found 
that expression of IFN-γ and the double-stranded RNA receptor TLR3 was lowered in the 
infected mosquito inoculation group compared to the needle inoculation group [22], which 
parallels our IFN-γ and TLR7 results from 3 hours post inoculation.  Although we initially 
anticipated that RelA would be up-regulated based on our preliminary transcript arrays, 
ultimately specific investigation of this gene revealed a significant down-regulation due to 
probing – perhaps due to the change in housekeeping gene utilized to normalize the data. 
 Interestingly, we found a general down regulation observed at 3 hours post inoculation, 
while there was no significant difference between the treatment and control groups at 6 hours 
post inoculation.  Similarly, in an in vitro experiment by Surasombatpattana et al., expression of 
IFN types I and II was not found to differ during DENV infection between SGE exposed and 
unexposed keratinocytes at 6 hours post exposure.  However, differential expression of other 
immune effectors was observed [15].  It must be considered, then, that the convergence of 
expression we observed at 6 hours post inoculation could be due to two things.   
 First, the convergence could be due to the waning effects on our targets of salivary 
components temporally removed from the initial expectoration event.  That is, probing and 
salivary proteins may have a more immediate effect on viral recognition and response 
components that diminishes with time.  Accordingly, Edwards et al. observed that when mice 
were inoculated with Cache Valley virus into areas of Ae. triseriatus spot-feeding with a delay 
between one and four hours post feeding, there was an enhancement of infection and serum 
antibody production.  When inoculation was delayed greater than four hours, or when 
inoculation was performed without delay but at a site distal to the location of spot-feeding, no 
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enhancement was observed [24].  Similarly, Styer et al. demonstrated that Culex tarsalis SGE-
induced enhancement of West Nile virus infection in mice was absent when SGE was injected 
into a distal location [14].  These experiments would suggest that the influence of salivary 
components on downstream immunological and infection characteristics is clustered both 
spatially and temporally at the bite site.  In contrast, DENV-2 inoculation delayed 30-60 minutes 
after Ae. aegypti spot-feeding on a distal location resulted in viremia levels similar to those 
elicited by infected-mosquito delivery in hu-NSG mice [17], warranting further study into the 
temporospatial nature of salivary influence.   
 Second, our observed convergence could be due simply to the interference of systemic 
responses reaching the opposing inoculation site, stemming from both the treatment and control 
groups existing on the same mouse.  Importantly, significant differences in expression were 
observed between the mosquito spot-feeding treatment group and the virus only control group at 
10 minutes and 3 hours post inoculation, indicating that the difference in observed expression, 
while likely conservative, is due to treatment differences and not the result of a systemic 
response at these time points. 
 We did not detect a significant difference in DENV titers in the inoculated ears between 
treatments, as shown in figure 3.1.  This lack of difference may be due to residual DENV RNA 
from the initial viral inoculum clouding the detection of meaningful changes in virion 
production.  Alternatively, DENV replication may not be occurring at detectable levels this early 
in the course of infection [50, 51].  Importantly, we did detect significantly greater levels of virus 
in the serum of mice that received mosquito probing concurrent with DENV inoculations in the 
days following infection, as shown in figure 3.2.  This finding is consistent with a previous 
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DENV infection in this IRF3/7 double knockout mouse model utilizing this same strain of 
DENV introduced via infected mosquito [28]. 
 Much of the work examining the effects of mosquito saliva on viral pathogens suggests 
that there is a shift away from an antiviral, TH1 immune response toward a TH2 response 
characterized by increased production of IL-4 and IL-10, among other immunological alterations 
[11, 13, 20, 22].  Additionally, inoculation via mosquito bite and exposure to saliva have been 
shown to enhance viral infection or potentiate infection in otherwise non-permissive models [10-
12, 14, 15, 17-21, 24].  The observed down-regulation of TLR7, RelA, IFN-γ, and IP-10 
transcripts at 3 hours post inoculation appears to reflect a shift away from an antiviral immune 
response, potentially generating an environment with reduced DENV recognition and antigen 
presentation, and diminished inhibition of viral replication and spread (depicted in figure 3.7). 
Upon superficial examination, the up-regulation of IFN-γ at 10 minutes post inoculation might 
seem to contradict this argument.  However, mosquito probing causes tissue injury during the 
search for capillaries, and IFN-γ is known to be up-regulated during skin injury repair [52].  
Additionally, IFN-γ is known to cause increased expression of and antigen presentation by MHC 
classes I and II [53].  Therefore, it is plausible that the tissue damage caused by mosquito 
probing is the initial stimulus for production of IFN-γ.  This IFN-γ may in turn cause an 
increased presentation of mosquito salivary proteins, some of which are known to have potent 
allergen potential, thereby instigating a shift away from an antiviral immune response toward a 
mosquito-allergen-based, TH2 immune response.  An obvious next step would be to assess these 
MHC complexes and immune effectors such as IL-4 and IL-10 that could indicate a TH2 shift, as 
well as other markers of tissue injury repair and allergen-based immune responses.  Based on the 
implications of our findings, down-regulation of our target transcripts early in the infection 
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Figure 3.7:  Cellular representation of the signaling pathways assayed and their involvement in 
DENV infection.  DENV enters the cell through receptor-mediated endocytosis, where it 1) fuses 
with the endosomal membrane to release its ssRNA genome into the cytoplasm or 2) is 
recognized by endosomal TLR7, which signals through RelA to induce production of MHC class 
I, IFN-β, and inflammatory cytokines that will then induce IFN-γ and IP-10.  The DENV dsRNA 
replication intermediate can be recognized by RLRs, NLRs, and TLR3 to further induce 
signaling via RelA.  IFN-β and IFN-γ can inhibit DENV translation and replication, while IP-10 
can competitively inhibit DENV binding to plasma membrane receptors, reducing infection of 
new cells.  Mosquito probing immediately prior to DENV inoculation could inhibit many of 
these interactions via the observed transcript down-regulation (represented by Xs) and thus allow 
more successful DENV transcription and translation (represented by dashed arrows). 
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process indicate important mechanisms by which mosquito probing and salivary protein 
expectoration serve to enhance the establishment of DENV infections in the vertebrate host. 
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CHAPTER 4 
IMPACT OF INDIVIDUAL SALIVARY PROTEINS FROM AEDES AEGYPTI ON 
DENGUE VIRUS PRODUCTION IN A HUMAN HEMATOPOIETIC CELL LINE 
 
4.1 Introduction 
 Dengue virus (DENV), the etiologic agent of dengue fever, is an enveloped, positive-
sense, single-stranded RNA virus of the genus Flavivirus.  DENV is maintained in a primarily 
anthroponotic cycle between humans and the Aedes aegypti mosquito [1].  Feeding by Ae. 
aegypti on vertebrate hosts involves the deposition of saliva, and thereby virus, into the skin [2-
5].  Mosquito saliva contains many proteins that modulate host hemostasis and immune 
responses, facilitating blood feeding and virus transmission [6, 7].  Ae. aegypti saliva also has 
been shown to contain allergenic proteins [8].  The vertebrate immune response to DENV 
infection is altered as a result of mosquito probing and the introduction of these immunogenic 
salivary proteins, thereby altering DENV infection kinetics and the likelihood of viral 
perpetuation [9].   
 Several of the individual proteins in saliva have been shown to elicit specific 
physiological consequences, with many disrupting events in hemostasis (e.g., collagen-binding to 
platelets or vasoconstriction) or modulating the production of TH1 and TH2 associated cytokines 
[10-19].  Additional experimental investigations of individual mosquito salivary proteins have 
shown that some serve as a boon to arboviral infection of the vertebrate, while other(s) may 
prove to be only a detriment [20-22].  Of particular relevance is a recent study demonstrating that 
DENV serotype 2 (DENV2) infection of Ae. aegypti salivary glands significantly lowers the 
abundance of many expectorated salivary proteins, while leaving the expression of others 
unaltered [23].  Three of these proteins were chosen for further study herein: an aegyptin (clade 
I; -14.1-fold), an adenosine deaminase (-2.8-fold), and a C-type lectin (indeterminate).   
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 Aegyptins are a family of GE-rich 30 kDa antigen with two proteins in Ae. aegypti, 
designated as clade I and clade II aegyptin [24].  Clade II aegyptin has been shown to induce 
positive skin-test reactions and antibody responses in sensitized humans, as well as disrupting 
hemostasis by binding collagen, inhibiting platelet aggregation and intereaction with von 
Willebrand factor [14, 15, 25].  As the clade I aegyptin noted above was the only aegyptin 
detected in the previous study, and due to the known characteristics of clade II aegyptin, clade II 
aegyptin protein was chosen for  further study [23]. 
 Adenosine deaminase is an enzyme that hydrolyzes adenosine to inosine and ammonia.  
The substrate, adenosine, has been associated with pain perception and mast cell degranulation 
[26, 27].  The degradation product, inosine, was shown to be over 100 times less effective then 
adenosine at inducing these effects, and was shown to inhibit the production of inflammatory 
cytokines [27, 28].   
 C-type lectins are a large family of calcium-dependent, carbohydrate-binding proteins, 
many of which are involved in cell-to-cell adhesion and innate immune responses [29].  This 
particular protein from Ae. aegypti has not been characterized beyond a putative homology.  
Instead, it was chosen due to its potential role as a receptor and contrast to the two chosen 
salivary proteins of known lower abundance. 
 The DENV2 infection-induced lowered abundance of some salivary proteins as compared 
to the maintenance of a steady-state expression of others suggested the possibility of a negative 
pressure by these lowered proteins on DENV perpetuation.  In order to determine if some aspect 
of this pressure exists within the vertebrate segment of the perpetuation cycle, we investigated 
the influence of the aforementioned individual, recombinant salivary proteins on DENV2 
production in the human, hematopoietic cell line, K562. 
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4.2 Materials and Methods 
4.2.1 Viruses 
 DENV serotype 2 (DENV2) strain 1232 was propagated as described previously, with 
modification [9]. Briefly, we inoculated T-75 flasks of confluent C6/36 cells with 100 µl of viral 
stock and incubated them for 30 min. Eight milliliters of M199E medium with 10% fetal bovine 
serum and 2% penicillin-streptomycin-amphotericin B (Fungizone) (P/S/F) was added. The flask 
was incubated at 37°C with 5% CO2 for 5 days, and subsequently the supernatant was collected 
for virus. The supernatant was found to contain 6 x 106 PFU/ml using a plaque assay as 
described previously in the supplemental material of reference [30], with modification. M199E 
medium containing P/S/F was used, and incubations occurred at 37°C. 
 
4.2.2 Mosquito rearing and inoculation 
 Laboratory strain Ae. aegypti  (Rockefeller) were maintained in an environmental 
chamber at 28°C and 75 to 80% humidity and subjected to a 16:8 light-dark photoperiod regimen 
until the time of use. Mosquitoes were provided with a water and 10% sucrose solution ad 
libitum, which was removed 24 h prior to blood feeding and replaced thereafter.  Approximately 
one week post emergence, female mosquitoes were allowed to feed on bovine blood in Alsever’ 
s anticoagulant via Hemotek feeding device (Discovery Workshops, Lancashire, England) 
containing DENV2 strain 1232, after which the blood-fed females were sorted. After 14 days, 
legs were removed and tested as previously performed as a proxy for dissemination [31].  
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4.2.3 Cloning and sequencing of target protein cDNA 
 RNA was extracted from a single, adult female Ae. aegypti that tested positive for DENV 
dissemination above using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). The head and 
thorax were placed in RLT buffer containing β-mercaptoethanol and extracted as per 
manufacture’s instructions with on-column DNase I treatment. cDNA was reverse transcribed 
from RNA using the oligo dT protocol of the SuperScript® III First-Strand Synthesis System 
(Invitrogen/Life Technologies, Carlsbad, CA). A gene-specific primer set was used for full 
transcript amplification of each target protein (Table 4.1) using the Platinum PCR Supermix 
(Invitrogen/Life Technologies, Carlsbad, CA).  Thermal cycler conditions were as follows: 94°C 
for 2 minutes; 35 cycles of 94°C for 30s, 55°C for 30s, 72°C for 2 minutes; 68°C for 5 minutes; 
4°C hold. PCR products were cloned into TOPO vectors and transformed into DH5α-T1 cells for 
amplification using the TOPO TA Cloning Kit (Invitrogen/Life Technologies, Carlsbad, CA).  
Plasmids were extracted from amplified broth culture using the PureLink® Quick Plasmid 
Miniprep Kit (Invitrogen/Life Technologies, Carlsbad, CA) and then sequenced for target 
verification using Sanger sequencing as follows.  Sequencing reactions were performed using 
100ng plasmid DNA in a maximum volume of 5uL.  A single M13 sequencing primer at 2uM 
concentration was added to reaction at a volume of 2uL.  Big Dye Terminator v3.1 (Applied 
Biosystems/Life Technologies, Carlsbad, CA) was added at a volume of 4uL.  The total 
sequencing reaction volume is 11uL. Controls were run as supplied with the BDTv3.1 reagent, 
namely pGEM-3Zf(+) double-stranded DNA control template and M13(-21) Control primer.  
Controls are set up in the same manner as samples and run on standard thermal cyclers.  
Sequencing reaction conditions according to ABI protocols were as follows: 96°C for 5 minutes; 
34 cycles of 96°C for 10s, 54°C for 5s, 60°C for 4 minutes; 4°C hold.  Sequencing products were 
	   83	  
cleaned up using Agencourt CleanSeq (Beckman Coulter, Indianapolis, IN) magnetic beads 
according to manufacturer’s protocol. Sequencing runs were performed on Applied Biosystems 
3130 Genetic Analyzers, 4-capillary electrophoresis instruments.  Previously run sample aliquots 
were added to sample plate as additional controls. 
 
Table 4.1: Primer sequences for PCR amplification of full length Ae. aegypti saliva proteins for 
cloning and recombinant expression. 
 
NCBI protein / 
nucleotide Description Forward (5’-3’) Reverse (5’-3’) 
gi|108878609 / 
XM_001651187.1 
Adenosine deaminase ATG AAA AAT CTA 
CTT ACA GCA ATT 
TTG GTC 
TTA AAC ACT TCC 
AGC CAC GAT ATC 
 Adenosine deaminase 
(no stop) 
 
 
AAC ACT TCC AGC 
CAC GAT ATC 
gi|18568318 / 
AF466606.1 
C-type lectin ATG GCT CTT TCA 
TTG TAT CTA ATC 
GCT GTT 
TTA CGC CTG TTC 
GCA CAC AAA G 
 C-type lectin (no stop)  
 
CGC CTG TTC GCA 
CAC AAA G 
 
4.2.4 Production of ADA and C-lectin 
 Genes encoding adenosine deaminase (1572 bp; ADA) and C-type lectin (462 bp; C-
lectin) were amplified without their stop codons from the previously created TOPO vector using 
Fail-Safe™ DNA polymerase (Epicentre, Madison, WI) and cloned into pFastBac HBM-TOPO 
vector (Invitrogen/Life Technologies, Carlsbad, CA). Recombinant baculoviruses producing the 
respective proteins with 6x His tag at their carboxyl terminus were constructed using Bac-to-Bac 
Baculovirus Expression System (Invitrogen/Life Technologies, Carlsbad, CA) as described by 
manufacturer’s instructions. Only supernatants from the infected sf9 cells were used for protein 
purification using Talon metal affinity resin (Clontech Laboratories Inc., Mountain View, CA). 
Infected supernatants were clarified from the cells debris by centrifugation (4000xg, 10 min) and 
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NP-40 non-ionic detergent was added to the final concentration of 1%. After one more 
centrifugation (8000xg, 30 min) clear supernatants were filtered using 0.2 µm filter and mixed 
with Talon resin (1v of resin: 50v of supernatant) overnight on a shaker at 4°C. After 
centrifugation (2000xg, 10 min) resin was washed 4 times with buffer containing 50 mM sodium 
phosphate, 300 mM sodium chloride and 15 mM of imidazole, pH 7.4. Proteins were eluted in 
the same buffer only containing 150 mM of imidazole. In order to obtain an imidazole-free 
solution for downstream experiments, buffer exchange against phosphate-buffered saline (PBS) 
using Zeba Spin desalting columns (Pierce/Thermo Scientific, Rockford, IL) was performed.  
The purity of the resulting protein-PBS solution was verified by 1-D gel SDS-PAGE stained with 
Coomassie Brilliant Blue (Figure 4.1). 
 
Figure 4.1: Gel Image of recombinant adenosine deaminase (lane 2 in imidazole, lane 3 in PBS) 
and putative C-type lectin (lane 4 in imidazole, lane 5 in PBS) with ladder (lane 1) and bovine 
serum albumin protein concentration standards (lanes 6-9; 0.25, 0.5, 1, and 1µg). 
 
4.2.5 Cell culture and infection 
 The human hematopoietic cell line K562 was obtained from ATCC (CCL-243) and 
maintained at 37°C with 5% CO2.  Complete media utilized was Iscove's Modified Dulbecco's 
Medium (IMDM) with GlutaMAX™ supplement (Gibco®/Life Technologies, Carlsbad, CA), 
10% fetal bovine serum, and 2.85% additional HEPES.  Cells were grown to >800,000 cells/ml 
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and then distributed to 200,000 cells per experimental well of a cell culture plate.  Cells were 
exposed to 0.1 MOI of DENV and 52ng of protein per well and incubated for one hour at 37°C 
with 5% CO2 with periodic mixing.  After incubation, cells were centrifuged at 900xg for 3 
minutes, media decanted, and then washed six times at a 1/10 dilution with 1X PBS to remove 
unbound virus and protein.  Cells were reconstituted in a final volume of 500µl per well and an 
additional 52ng of protein was added to each well for the duration of the experiment.  Each 
treatment was performed in triplicate wells.  After 24 hours, the contents of each well were 
transferred to 1.5ml microcentrifuge tubes and centrifuged at 900xg for 3 minutes.  400ul of 
supernatant was transferred to new tubes. The remaining volumes and cell pellets were washed 
three times in 500µl 1X PBS per wash.  The Ae. aegypti salivary proteins utilized in this 
experiment were the recombinant adenosine deaminase and C-type lectin, as well as a 
recombinant aegyptin (from gi|94468546) generously provided by Dr. Eric Calvo (National 
Institutes of Health/NIAID).  The aegyptin was expressed as described previously in HEK293 
cells with a 6x-His tag [14].  For the purpose of comparison to non-salivary proteins, we also 
examined the effect of three additional proteins: commercially available casein and bovine serum 
albumin (BSA), as well as a recombinant protein from Rickettsia conorii, rOmpB, generously 
provided by Dr. Juan Martinez (Louisiana State University).  rOmpB was expressed as described 
previously [32]. 
 
4.2.6 Nucleic acid extraction and quantification 
 DENV RNA was extracted from culture supernatants using the MagMax-96 Viral RNA 
Isolation Kit (Ambion/Life Technologies, Carlsbad, CA) and from cell pellets using the 
MagMax-96 Total RNA Isolation Kit (Ambion/Life Technologies, Carlsbad, CA) without DNase 
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I treatment in order to include cellular DNA.  DENV RNA was detected by quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) assay with the Superscripts III® Platinum® 
One-Step qRT-PCR system (Invitrogen/Life Technologies, Carlsbad, CA) on the LightCycler 
480 (Roche Diagnostics Corp., Indianapolis, IN) and DENV concentration standards derived 
from plaque assays as previously described [20, 31].  Cellular DNA was detected by targeting 
the nucleotide sequence of endogenous retrovirus ERV-3 using the GoTaq® qPCR Master Mix 
(Promega, Madison, WI) in a 20µl reaction volume: 10µl of Master Mix, 0.4µl of each 10µM 
primer, and 4.2µl H2O.  ERV-3 primer sequences were taken from a previous publication and 
reproduced here as follows: Forward – 5’- CAT GGG AAG CAA GGG AAC TAA TG -3'; 
Reverse – 5’- CCC AGC GAG CAA TAC AGA ATT T -3' [33].  Cycling conditions were as 
follows: 95°C for 5 minutes; 40 cycles of 95°C for 10 s, 58°C for 1 minute. 
 
4.2.7 Statistical analysis 
 An ANOVA with uncorrected p values, comparing all treatments to the control (“Virus 
only”) was performed.  Significance was assessed using an α=0.05.  Arbitrary ERV-3 values 
were established by declaring a Cp value of 35 to equal one copy and calculating the 
corresponding arbitrary values for each treatment using an efficiency of two. 
 
4.3 Results 
4.3.1 Uncorrected DENV titers 
 In this study we investigated the effect of individual salivary proteins on DENV 
production in the hematopoietic cell line, K562.  Virus detection in the supernatant was 
performed using a fixed volume.  Quantification in this manner resulted in no significant 
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difference in DENV titer between salivary protein or comparison proteins treatments when 
compared to Virus only control (Figure 4.2, left panel).  Virus detection in the cell pellets was 
performed using the entirety of the pellet processed into a fixed elution volume.  Quantification 
of DENV in these pellets resulted in a significantly lower titers in C-lectin treated wells (mean of 
53.7 PFU*/mL) compared to Virus only wells (mean of 147.9 PFU*/mL), with no other 
significant differences as compared to Virus only wells (Figure 4.2, right panel).  Interestingly, 
however, there was a substantial difference in the quantity of cells per well in each treatment 
following the 24 hour incubation.  With mean values of 263.7 and 254.5 arbitrary units, 
respectively, the cell quantities in aegyptin and ADA treated wells were significantly greater than 
in the Virus only wells, with a mean of 135.4.  The mean cell quantity of C-lectin treated wells 
was between that of ADA and Virus only, with the comparison proteins having similar quantities 
to those of the Virus only wells (Figure 4.2).  
 
4.3.2 Normalized DENV titers 
 Due to the variability in cell quantity, we normalized the quantity of viral RNA in the 
supernatant and within the cell pellets to the quantity of cells detected.  This normalization 
resulted in fairly uniform values for DENV in the supernatant of the three comparison proteins, 
as well as significant decreases within the aegyptin (mean of 0.126) and C-lectin (mean of 0.139) 
treatments when compared to Virus only control wells (mean of 0.190; Figure 4.3, left panel).  
The normalization of intracellular DENV did not dramatically alter the relative values for each 
treatment.  However, these subtle changes to the means resulted in all treatment wells, with the 
exception of ADA, testing as significantly lower than Virus Only control (Figure 4.3, right 
panel). 
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Figure 4.2: Uncorrected DENV titers and arbitrary quantity of K562 cells per well.  Left panel 
represents DENV titers in the supernatant (left axis, bars) overlaid with quantity of K562 cells 
(right axis, square points) in arbitrary units based upon quantification of the human genome by 
targeting ERV-3 in the cell pellet.  Right panel represents DENV titers measured in the cell 
pellets; panel data corresponds to axes as in left panel.  DENV titers were significantly lower in 
C-lectin treated wells compared to Virus only wells.  K562 cells were significantly greater in 
number in Aegyptin and ADA treated wells when compared to Virus only wells (p≤0.05).   
 
 
 
 
Figure 4.3: DENV titers normalized to quantity of cells per well.  Left panel represents DENV 
RNA in the supernatant normalized to copies of ERV-3 in the cell pellet by subtracting the Cp 
value of ERV-3 from the Cp value of DENV, and then taking the reciprocal.  Right panel 
represents DENV RNA within the cell pellets normalized to ERV-3 as in left panel.  Asterisks 
represent treatments significantly different from Virus only (p≤0.05). 
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4.4 Discussion 
 This study represents the first investigation of the effect of individual vector salivary 
proteins on DENV production in a hematopoietic cell line.  The differential changes in DENV 
RNA among Ae. aegypti salivary protein treated cells infected with DENV2, strain 1232 
occurred in an unexpected pattern.  Specifically, the hypothesis upon initiating this study was 
that proteins previously found in lower abundance due to DENV2, strain 1232 infection of the 
salivary glands (i.e., aegyptin and ADA) would negatively impact DENV production, whereas 
other salivary proteins (i.e., C-lectin) would have the opposite effect or otherwise be ineffectual 
[23].  However, upon normalization, we found that while treatment with aegyptin did lower 
DENV2 production into the supernatant significantly, as anticipated, treatment with ADA 
lowered DENV2 production to a degree that was not significant.  Further, C-lectin treatment 
performed in the opposite manner as expected, lowering DENV2 production to a level similar to 
that of aegyptin treated wells.  Importantly, treatment in the present study with the non-mosquito 
proteins included for the purposes of comparison did not elicit changes to DENV2 production 
that were significantly different from those of Virus only control, suggesting that the above 
alterations to DENV2 production are specific to the salivary proteins utilized in this study. 
 We additionally assessed DENV2 RNA within the cells themselves in order to determine 
if changes to DENV2 production into the extracellular environment were related to intracellular 
alterations.  Surprisingly, we detected lower mean values of normalized DENV2 RNA in all 
protein treatments, both salivary and non-salivary, relative to Virus only control, of which all 
except ADA were significant.  In contrast, a previous study has shown that co-inoculation of 
DENV (unspecified serotype) and individual Ae. aegypti salivary proteins onto human 
keratinocytes in vitro induced significantly increased intracellular viral RNA when compared to 
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virus alone for all proteins assessed, including an adenosine deaminase [21].  Curiously, there 
does not appear to be a pattern in the means of DENV2 RNA relating the intracellular and 
extracellular values in the present study. 
 Although not specifically assessed in this study, the differences between the intracellular 
and extracellular DENV2 RNA detected could suggest that the various protein stimuli tested 
herein elicit changes to the mechanism of viral escape into the supernatant.  It is reasonable to 
state that treatment with a protein (of apparently many types) lowers DENV2 RNA within the 
cell, and for the most part, to a similar degree.  Yet, in contrast, only treatment with specific 
salivary proteins lowered DENV2 RNA detected in the supernatant.  This then begs the question 
of how the non-mosquito protein treated wells presented extracellular DENV2 values 
approximating that of Virus only control, when aegyptin and C-lectin treated wells remained 
significantly lower.  To answer this question, additional, specifically targeted investigations are 
required, but there are multiple, potentially overlapping, possibilities.  First, increased lysis, via 
apoptosis or other means, of the cells in the non-mosquito protein treated wells may be 
occurring, thereby releasing increased DENV2 RNA into the supernatant.  However, this is 
unlikely without a concomitant increase to the number of cells, given that the number of cells 
detected was similar between these wells and those of Virus only control at this time point.  
Second, an increase in the budding rate of virions into the supernatant in the non-mosquito 
protein treated wells could compensate for a slowed intracellular replication.  In a tangentially 
related study, altering intracellular pathways via introduction of a kinase inhibitor resulted in 
alterations to virion production and secretion of virus particles and viral genomic RNA [34].  
Third, the reductions in supernatant titers could be the result of the increased quantity of cells, as 
newly produced virions would be capable of infiltrating the additional cells, and thereby 
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reducing the net extracellular measure.  Alternatively, the increased quantity of cells could result 
in an increase to phagocytosis and destruction of extracellular virions and RNA.  These scenarios 
are, of course, purely speculative at this time. 
 It is evident that co-exposure of K562 cells to DENV2 and recombinant, Ae. aegypti 
salivary proteins elicits alterations in detectable DENV2 RNA as compared to the Virus only 
control.  However, before proceeding further into in vitro investigations of the influence of 
individual salivary proteins on DENV2 virion production in this and additional, human cell 
types, it will be critical to establish additional controls and assays for the various scenarios 
outlined above.  By doing so we will gain an understanding of the mechanistic impact of these 
proteins, and thereby a knowledge of novel, potential targets for the disruption of DENV2 
pathogenesis. 
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CHAPTER 5 
AEDES AEGYPTI SALIVARY PROTEIN “AEGYPTIN” CO-INOCULATION 
MODULATES DENGUE VIRUS INFECTION IN THE VERTEBRATE HOST1 
 
5.1 Introduction 
 Dengue virus (DENV) is maintained in a primarily anthroponotic cycle between humans 
and the Aedes aegypti mosquito [1].  Feeding by Ae. aegypti on vertebrate hosts results in the 
simultaneous introduction of virus and saliva into the skin [2-5].  This saliva contains many 
pharmacologically important proteins that modulate host hemostasis and immune responses, 
which in turn facilitate blood feeding and virus transmission [6-8].  Additionally, Ae. aegypti 
saliva has been shown to contain allergenic proteins [9].  The vertebrate immune response to 
DENV infection may be altered as a result of the immunogenic nature of these salivary proteins, 
thereby altering DENV infection kinetics.  
 The effects of salivary proteins on mosquito-borne viral infection have been reviewed 
previously, and include alterations in cytokine production and potentiation of infection in 
otherwise non-permissive models [6, 10, 11].  More recently, Ae. aegypti saliva has been shown 
to induce alterations in leukocyte recruitment during West Nile virus infection, and shift the 
cytokine profile from a Th1 toward a Th2 type immune response during chikungunya virus 
infection [12, 13].  In the context of DENV infection, the addition of Ae. aegypti saliva in vitro 
resulted in the reduced production of antimicrobial peptides and interferons, thereby increasing 
viral titers [14].  Allowing Ae. aegypti to feed on IRF-3/7 -/- -/- mice immediately before 
intradermal injection of DENV resulted in the down-regulation of multiple innate immune 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1This chapter previously appeared as McCracken M K, Christofferson R C, Grasperge B J, Calvo 
E, Chisenhall D M, Mores C N. 2014. Aedes aegypti salivary protein “aegyptin” co-inoculation 
modulates dengue virus infection in the vertebrate host. Virology 27;468-470C:133-139.  It is 
reprinted by permission of Elsevier.  
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transcripts and increased DENV viremia titers [15].  Additionally, Ae. aegypti saliva has 
increased the prevalence of disease signs and extended the viremic period in DENV-infected, 
humanized mice [16].  
 As an important step in the characterization of mosquito saliva, researchers have 
examined the composition of Ae. aegypti salivary glands at the transcriptional level and protein 
expression level [7, 17-23].  Work has been done to ascribe function to some of these salivary 
components and investigate their individual effects on vertebrate hemostasis and immune 
response outside the context of a viral infection [8, 17, 24-31].  Additionally, Ae. aegypti saliva 
has been shown to elicit specific IgG and IgE responses in humans [23, 32].  Recent studies have 
described the effect that DENV infection has on protein expression in the salivary glands or 
expectorated saliva and postulates how these changes could be relevant to virus transmission [33, 
34].  Among the proteins that were found in lower abundance in Ae. aegypti  saliva as a result of 
DENV infection was a member of the GE-rich 30 kDa antigen family, designated in Ae. aegypti 
as “aegyptins” [8, 35].  The decreased expression of this protein during DENV infection could 
suggest that it supplies negative pressure on viral perpetuation.  This pressure may be inherent to 
the aegyptin protein family and perhaps impacts transmission or establishment of infection. 
 The archetypal protein of the 30 kDa antigen family in Ae. aegypti has been shown to 
perform two distinct roles within the vertebrate.   First, as an allergen, aegyptin has been shown 
to induce positive skin-test reactions and antibody responses in sensitized humans [36].  Second, 
aegyptin has demonstrated the ability to bind to collagen, inhibiting platelet aggregation and 
interaction with von Willebrand factor, which could facilitate blood feeding by reducing the 
formation of blood clots [8, 28].  
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 Due to the involvement of aegyptin with both the vertebrate immune response and the 
clotting cascade, we explored the impact of aegyptin within the context of a DENV infection.  
Recombinant aegyptin was used for in vivo evaluation of the effects of this protein on the murine 
immune response to DENV and the resulting infection in the inoculation site, draining lymph 
nodes, and in circulation. 
 
5.2 Materials and Methods  
 All experiments met the approval and conditions of the LSU Institutional Animal Care 
and Use Committee (protocol #12-079).  LSU IACUC procedures and policies adhere to and 
comply with the guidelines stated in the NIH Guide for the Care and Use of Laboratory Animals. 
 
5.2.1 Mice  
 Mice were the generous gift of Dr. M. Diamond (Washington University, St. Louis, MO) 
with permission from Dr. T. Taniguchi (University of Tokyo, Tokyo, Japan).  These IRF-3/7 -/- -/- 
mice are on a C57Bl/6 background and lack functional IRF 3 and 7, and as such have a deficient, 
but not abrogated, type I IFN response [37].  
 
5.2.2 Virus 
 Dengue serotype 2 (DENV2), strain 1232 was propagated as described previously, with 
modification [38].  Briefly, we inoculated a T-75 flask of confluent Vero cells with 100 µl of 
viral stock and incubated for 30 minutes.  Eight mL of Medium 199 with Earle’s salts (M199E) 
with 10% fetal bovine serum and 2% penicillin / streptomycin / amphotericin B was added.  The 
flask was incubated at 37°C with 5% CO2 for 5 days and subsequently the supernatant was 
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collected for virus at peak titer.  The viral titer of the supernatant was determined using a plaque 
assay as described previously in supplemental material, with modification [39].  The complete 
medium stated above was used and incubations occurred at 37°C.  This strain was originally 
isolated from a patient in Indonesia in 1978 (personal communication, R. Tesh).  As of this study, 
it has been passaged four times in Vero cells, and then alternatingly passaged between C6/36 
(Aedes albopictus cell line) and Vero twice. 
 
5.2.3 Mouse Exposure and Sample Collection 
 Recombinant aegyptin was generated at a concentration of 9 uM in 25mM Tris 150mM 
NaCl, pH 7.4.  It was expressed as described previously in HEK293 cells and has a 6x-His tag 
[8].  Aegyptin was diluted 1/10 in 0.2µm-filtered 1X phosphate-buffered saline (PBS) for 
experimentation. 
 
5.2.3.a Inoculation site mice 
 A total of 17 male and female mice, age fifteen weeks, were divided into four treatment 
groups and inoculated in the pinnae of both ears via 25µL intradermal injection.  These groups 
were DENV (n=5), DENV + aegyptin (n=5), aegyptin (n=3), and a mock inoculation (n=4).  The 
compositions of the inocula were as follows: DENV – 10µL DENV (1x105 PFU total in cell 
culture supernatant) + 15µL 1X PBS; DENV + aegyptin – 10µL DENV + 2µL aegyptin 1/10 + 
13µL 1X PBS; aegyptin only – 10µL age-matched cell culture supernatant + 2µL aegyptin 1/10 + 
13µL 1X PBS; mock – 10µL age-matched cell culture supernatant + 15µL 1X PBS.  Forty-eight 
hours later, mice were euthanatized according to our IACUC protocol, and blood was collected 
via cardiac puncture using ethylenediaminetetraacetic acid (EDTA)-coated syringes and then 
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placed into EDTA-coated BD Microtainer®™ tubes (Becton, Dickinson, and Company, Franklin 
Lakes, NJ).  This blood was used for the creation of blood films for quantification of circulating 
leukocytes and then centrifuged at 1000 relative centrifugal force (rcf) for 10 minutes for plasma 
separation for use in cytokine protein and viral RNA analysis.  Inoculated ears and draining 
submandibular lymph nodes were also collected and processed for cytokine protein and viral 
RNA analysis.  Individual mouse ears and lymph nodes were disrupted and homogenized in 
100µL and 20µL, respectively, of 1X PBS using the TissueLyser (QIAGEN, Valencia, CA) for 
two cycles of 2 minutes at 25Hz. For cytokine analysis, 60µL and 10µL of the homogenized ear 
and lymph node solutions were placed in 440µL and 40µL, respectively, of 
radioimmunoprecipitation assay (RIPA) lysis buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) diluted 1/5 in 1X PBS containing protease 
inhibitor (cOmplete, Mini, EDTA-free protease inhibitor cocktail tablets, Roche, Indianapolis, 
IN).  For viral RNA detection, 20µL and 5µL of the homogenized ear and lymph node solutions 
were placed into 600µL and 350µL, respectively, of QIAGEN’s RLT buffer with β-
mercaptoethanol and vortexed.  RNA was extracted using the RNeasy Tissue Mini Kit (QIAGEN, 
Valencia, CA).  
 
5.2.3.b Serially bled mice 
 A total of 19 female mice, age ten±two weeks, were divided into two treatment groups 
and inoculated in the pinnae of one ear or rear footpad via 25µL intradermal injection.  These 
groups were DENV (n=9) and DENV + aegyptin (n=10).  The compositions of the inocula were 
as above, with a DENV titer determined to be 6.7x104 PFU total.  Mice were bled via 
submandibular vein puncture immediately prior to inoculation and then daily for the next 6 days 
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[40].  This blood was collected in microcentrifuge tubes, allowed to clot for thirty minutes at 
room temperature, and then centrifuged at 3300 rcf for four minutes.  Clarified serum was 
collected and placed into clean microcentrifuge tubes for nucleic acid extraction using the 
MagMax-96 Total Nucleic Acid isolation kit (Ambion/Life Technologies, Carlsbad, CA) and 
subsequent quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 
measurement of viremia. 
 
5.2.4 Hematology 
 Differential leukocyte counts were performed in a blinded manner by a board-certified 
veterinary clinical pathologist, as previously described, in order to examine circulating leukocyte 
populations during the inoculation site and serially bled mouse studies [41].  Briefly, blood films 
were made within one hour of collection.  Blood films were Wright Giemsa stained and counted 
in duplicate for differentiation of lymphocytes, monocytes, eosinophils, and basophils.  Blood in 
EDTA was diluted 1:100 in 2% acetic acid and incubated for 10 minutes at room temperature.  
Total nuclei were counted in duplicate for each mouse using this blood-acetic acid solution on a 
hemocytometer in order to derive absolute leukocyte concentrations.  Absolute leukocyte 
concentrations and differential counts were then used to calculate the absolute differential 
leukocyte concentrations. 
 
5.2.5 Viral Detection 
 Before inoculation, DENV was titered via plaque assay and experimental titers from cell 
culture supernatant were confirmed by qRT-PCR as previously described [38]. DENV RNA was 
extracted using the MagMax-96 Total Nucleic Acid isolation kit (Ambion/Life Technologies, 
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Carlsbad, CA) or RNeasy Tissue Mini Kit (QIAGEN, Valencia, CA).  Serum samples were 
brought to volume where necessary with BA-1 diluent (M199E, 10% bovine serum albumin, 0.1 
g/L L-glutamine, 2.2 g/L sodium bicarbonate, 25mM HEPES, 2% penicillin / streptomycin / 
amphotericin B, titrated to 7.4 pH with Tris and HCl) and kits were run per manufacturers’ 
instructions [42].  Detection of DENV RNA in mice was performed using the Superscript® III 
Platinum® One-Step qRT-PCR system (Life Technologies, Carlsbad, CA).  Serial dilutions of 
DENV culture supernatant (from above) were quantified via plaque assay, extracted alongside 
samples, and used to generate the qRT-PCR standard curve for estimation of DENV titer.  Thus, 
viral concentrations are expressed as PFU-equivalents/mL where appropriate, symbolized as 
PFU*/mL. 
 
5.2.6 Cytokine Measurement 
 Granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, IFN-
γ-inducible protein-10 (IP-10), tumor necrosis factor (TNF)-α, interleukin (IL)-1a, IL-2, IL-4, 
IL-5, IL-6, IL-10, and IL-12p70 were measured in the inoculation sites, draining lymph nodes, 
and serum at 48 hours post inoculation in the inoculation site cohort of mice using the 
Milliplex® MAP Mouse Cytokine/Chemokine kit (EMD Millipore, Billerica, MA) as per 
manufacturer’s instructions. 
 
5.2.7 Statistical Analysis  
 Tissue viral titers and cytokine levels were statistically analyzed using analysis of 
variance (ANOVA).  Leukocyte values were analyzed using odds ratios.  These analyses were 
performed in SAS 9.13 (Carey, NC).  Viremia titers were statistically analyzed using grouped t-
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test by day in GraphPad Prism version 6.0b for Mac OS X (San Diego, CA).  Significance is 
reported at the α=0.05 level. 
 
5.3 Results 
5.3.1 Inoculation site mice 
5.3.1.a Viral titers 
 DENV titers were measured at 48 hours post inoculation in the inoculated ears and 
draining submandibular lymph nodes of mice inoculated with DENV + aegyptin or DENV only.  
DENV titers in the ears of DENV + aegyptin inoculated mice had a mean of 1.65 x 106 
PFU*/mL, while the inoculated ears of mice that received DENV alone had a significantly 
greater mean titer of 3.38 x 106 PFU*/mL (p=0.0057).  The lymph nodes of DENV + aegyptin 
inoculated mice did not differ significantly from mice inoculated with DENV alone (p=0.0678) 
with mean titers of 7.21 x 105 and 1.42 x 106 PFU*/mL, respectively. (Figure 5.1) 
 
5.3.1.b Cytokine responses 
 The cytokines GM-CSF, IFN-γ, IP-10, TNF-α, IL-1a, IL-2, IL-4, IL-5, IL-6, IL-10, and 
IL-12p70 were assessed in the inoculated ears, draining submandibular lymph nodes, and the 
serum of mice inoculated with DENV + aegyptin, DENV alone, aegyptin alone, and those that 
received a mock inoculation as outlined above.  All differences stated are significant (p≤0.05).  
In the ears (Figure 5.2A), the concentrations of IFN-γ and IL-2 were found to differ between all 
treatment groups except DENV + aegyptin compared to DENV alone.  IL-10 differed among all 
comparisons except DENV + aegyptin compared to DENV alone and aegyptin alone compared 
to mock.  IP-10 differed when comparing DENV + aegyptin to aegyptin alone or mock, and  
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Figure 5.1: DENV titers in inoculated ears and draining submandibular lymph nodes at 48 hours 
post inoculation.  DENV titers, expressed as PFU-equivalents/mL (PFU*/mL) were significantly 
lower in the ears of mice that received co-inoculation of DENV + aegyptin (AV) as compared to 
the cohort that received DENV only (V, p=0.0057), as indicated by an asterisk.  DENV titers 
were not found to be significantly different in the lymph nodes (p=0.0678), although they 
followed a similar trend as those of the ears.  Associated bars represent standard error of the 
means. 
 
mock differed from DENV alone.  IL-6 differed only in ears inoculated with aegyptin alone 
compared to DENV alone.  IL-4 and IL-12p70 were below the limit of detection in all treatment 
groups.  All other cytokines displayed no significant differences between treatment groups, and 
no cytokines were found to differ in the ear between DENV + aegyptin and DENV alone 
(p>0.05).  In the draining submandibular lymph nodes (Figure 5.2B), GM-CSF, IFN-γ, and IL-6 
were found to differ significantly between DENV + aegyptin compared to DENV alone, aegyptin 
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alone, and mock treatment mice.  IL-5 in DENV + aegyptin inoculated mice differed from mice 
inoculated with DENV alone.  TNF-α differed among all comparisons except DENV + aegyptin 
compared to DENV alone and aegyptin alone compared to mock inoculated mice.  IP-10 differed 
only between aegyptin alone compared to DENV + aegyptin or DENV alone.  Again, IL-4 and 
IL-12p70 were below the limit of detection and all other cytokines displayed no significance 
between treatment groups (p>0.05).  Cytokine concentrations in the serum were not found to be 
significantly different between any treatment groups (p>0.05, data not shown). 
 
5.3.1.c Hematology 
 The percentages (counts) and concentration (per µL) of circulating leukocytes were 
determined as described above for all four treatment groups.  All stated differences are 
significant (p≤0.05) as determined using odds ratios.  The eosinophil counts in the DENV + 
aegyptin inoculated mice were more likely to be elevated when compared to mice inoculated 
with DENV alone, as well as in mock inoculation compared to DENV alone.  The monocyte 
counts were correspondingly more likely to be lower in these comparisons as well as in mice 
inoculated with aegyptin alone compared to DENV alone.  Neutrophil counts were found more 
likely to be lower between mice inoculated with aegyptin alone as compared to all other 
treatments.  Lymphocyte counts were correspondingly more likely to be higher in the aegyptin 
alone group compared to all other treatment groups, as well as in mock inoculated mice 
compared to those inoculated with DENV alone.  All other comparisons of counts, the leukocyte 
concentrations (data not shown), and total nucleated cell concentrations (data not shown) were 
not found to differ significantly (p>0.05).  The comparison of leukocyte counts from the 
aegyptin + virus inoculation cohort as compared to the virus only inoculation cohort is displayed 
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Figure 5.2: Cytokine concentrations in the inoculated ears (A) and draining submandibular 
lymph nodes (B) at 48 hours post inoculation.  The y-axis displays concentration in pg/mL and 
the x-axis denotes treatment groups (AV = DENV + aegyptin, V = DENV only, A = aegyptin 
only, M = mock inoculation). Significant comparisons are indicated by an asterisk (p≤0.05).  
Associated bars represent standard error of the means. 
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in Figure 5.3.  The odds ratios with associated 95% confidence intervals and p values for this and 
all other comparisons of counts are in Appendix 4. 
 
 
Figure 5.3: Comparison of circulating leukocyte percents (counts) at 48 hours post inoculation 
for the DENV + aegyptin inoculated cohort (AV) compared to the virus only cohort (V).  
Comparisons of each leukocyte were performed using odds ratios and significance is indicated 
by an asterisk (p≤0.05).  Ninety-five percent confidence intervals are displayed. 
 
5.3.2 Serially bled mice 
5.3.2.a Viremia 
 DENV viremia titers were measured each day for six days following inoculation in both 
the DENV + aegyptin and DENV alone treatment groups.  These titers were found to differ 
significantly between the two treatment groups on day two post inoculation, which corresponds 
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to the difference observed in the inoculation sites at 48 hours post inoculation, and on day five 
post inoculation (p≤0.05). (Figure 5.4) 
 
 
 
Figure 5.4: DENV viremia titers in serum samples on the first six days post inoculation.  DENV 
titers, expressed as PFU-equivalents/mL (PFU*/mL) were significantly lower in mice inoculated 
with DENV + aegyptin as compared to those inoculated with virus alone on day 2 post 
inoculation.  DENV titers were significantly higher in mice inoculated with DENV + aegyptin as 
compared to those inoculated with virus alone on day 5 post inoculation.  Significance is 
indicated by an asterisk (p≤0.05).  Associated bars represent standard error of the means. 
 
5.4 Discussion  
 The 30 kDa antigen family of proteins contains multiple alleles and splice variants that 
are compositionally similar, consisting of two domains and possessing similar molecular weights.  
Prior analysis has revealed that these aegyptins represent two subclades within Aedes (designated 
I and II)[35].  Analysis of expectorated saliva from DENV2 infected Ae. aegypti using 2D gel 
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electrophoresis and LC-MS/MS has previously identified a subclade I aegyptin (gi|18568322) 
that was reduced 14.1-fold when compared to saliva from uninfected mosquitoes [34].  This 
aegyptin has also been referred to as “SAAG-4,” which has demonstrated the capacity to 
suppress IFN-γ expression while elevating IL-4 expression by CD4+ T cells outside the context 
of a viral infection [26].  The recombinant aegyptin used in the current study in vivo is a member 
of subclade II (gi|94468546) and is the archetypal aegyptin utilized in the biopharmaceutical 
characterization of the capacity to inhibit clotting [8, 28].  This aegyptin is also identical in 
sequence to that of Ae. aegypti salivary allergen “Aed a 3” (gi|205525920), a protein shown to 
induce allergic responses in both mice and humans [43].  Additionally, other researchers have 
found an association between serum reactivity to Aed a 3 and the dengue fever (mild) disease 
state in clinical patients in Thailand [44].  While the two aegyptin groups represent distinct 
subclades, the acidic (glycine-, aspartic acid-, and glutamic acid-rich) aminoterminal domain and 
the more complex carboxyterminal domain characteristic of this protein family remain conserved 
[35]. 
 The goal of this study was to determine the impact of the Ae. aegypti salivary protein 
aegyptin on DENV infection kinetics and the corresponding vertebrate immune response, in light 
of the allergenic and anti-clotting effects already ascribed to this protein.  We designed two in 
vivo murine experiments examining the two vertebrate facets critical to mosquito-borne viral 
transmission: establishment of DENV infection within the bite site of the vertebrate host, and 
systemic infection (circulation) that enables transmission from the vertebrate to naïve mosquitoes.  
The time point of the first experiment, 48 hours post inoculation, is the day most often observed 
for the onset of DENV viremia in these mice [45], and as such potential differences seen in the 
bite site and draining lymph nodes were assumed to be near their peaks.  Mice for the second 
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experiment were examined daily through the end of viremia for differences that have the 
potential to lead to differential acquisition by the vector, such as differences in the magnitude of 
viremia titers or day of viremia onset [46].   
 The addition of aegyptin to the DENV inoculum resulted in significantly decreased viral 
titers in the inoculated ears 48 hours post inoculation, which could provide a rationale for the 
DENV2-induced reduction of aegyptin in the saliva of infected mosquitoes.  It may be that this 
reduction in expectorated aegyptin decreases the likelihood of an allergen-related or otherwise 
inflammatory immune response at the bite site.  As an extreme example, humans bitten by 
mosquitoes lacking the ability to expectorate saliva failed to manifest wheals [47].  Mosquito 
saliva also has been shown previously to induce numerous immunological reactions at the site of 
inoculation including T-cell-mediated hypersensitivities, IgE-independent mast cell 
degranulation, and immune cell recruitment [9].  Lymph node GM-CSF, IFN-γ, IL-5, and IL-6, 
as well as the percentage of eosinophils in circulation, were observed to be greater in the DENV 
+ aegyptin mice than in mice inoculated with DENV alone at this time point.  GM-CSF was 
demonstrated previously to promote growth, maturation, and survival of eosinophils, a pro-
inflammatory granulocyte typically associated with immune responses to allergens [48, 49].  IL-
6 is known to be an important mediator of the acute phase response to infection and other 
antigenic stimuli, and its influences have been reviewed previously [50].  IFN-y and IL-5 
promote the activation and survival of phagocytes and eosinophils, respectively, influence B cell 
isotype switching events, and are involved in allergic immune responses [51-54].  A reduction or 
alteration in these immune responses via a reduction in expectorated aegyptin could benefit the 
establishment of DENV within the vertebrate host.  As a consequence of lessened aegyptin in the 
site of viral establishment, there may be less non-specific destruction of virions or infected cells 
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by local inflammation, cytokine-mediated cellular activation, and eosinophil-derived 
degranulation. 
 Importantly, the addition of aegyptin to the DENV inoculum of the serially bled cohort of 
mice resulted in an approximately three-fold reduction in viremia titer on day two post 
inoculation, which corresponds to the decrease seen in the inoculation site at 48 hours post 
inoculation. Analogously, a reduction in expectorated aegyptin, as was observed in DENV 
infected Ae. aegypti mosquitoes, may result in greater viremia titers at this time point, which has 
been shown to lead to increased acquisition rates by mosquitoes from human clinical patients [34, 
46].  The increase in DENV + aegyptin viremia titer seen on day 5 post inoculation (mean = 4.36 
PFU*/mL) may not result in meaningful differences in transmission when compared to the 
DENV alone cohort (mean = 1.39 PFU*/mL) given the relatively minimal magnitude of these 
titers.  Alternatively, the significance of changes at these two time points may have a more 
epidemiological importance.  Mosquitoes have been shown to successfully acquire DENV up to 
two days prior to the onset of illness in human cases, at which time these individuals may seek 
medical attention or otherwise sequester themselves from access by mosquitoes [55].  As such, 
the minimization of contact between clinically ill individuals and mosquitoes might select for a 
viral phenotype that induces decreased expression of aegyptin, thereby resulting in greater early 
(potentially prodromal) viremia rather than late viremia enhancement. 
 In conclusion, the influence of aegyptin on DENV infections of mice was exemplified by 
decreased viral titers early in the infection in inoculation sites and in circulation, and by a day 
with increased viremia titer late in infection.  These modulations of DENV infection 
corresponded to increases in cytokines with known functions in pro-inflammatory and allergen-
mediated immune responses, as well as an increased likelihood of eosinophil production.  
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Together, these data support a role for aegyptin in the modification of the host immune response 
during DENV infection. The role of aegyptin in a naturally introduced DENV infection of 
humans may be additionally influenced by other, co-expectorated saliva proteins, as well as prior 
immunity to aegyptin or the same.  Future studies should seek to further characterize pro- and 
anti-viral aspects of mosquito saliva-DENV interactions in the context of human infection and 
immunity. 
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CHAPTER 6 
DISCUSSIONS AND CONCLUSIONS 
 
6.1 Introduction 
 Presented in this dissertation are four experimental studies investigating the influence of 
Aedes aegypti saliva on the vertebrate host response to dengue virus (DENV) infection, of which 
chapters 3 and 5 are currently published in peer-reviewed scholarly journals. Rather than the 
chronological order in which each study was performed, the chapters presented herein are 
organized by their relative position in the transmission cycle of DENV and then by the 
deconstruction and analysis of factors expected to impact the perpetuation of DENV.  Particular 
emphasis in each study was given to factors and time points relevant to transmission of DENV to 
and from the vector and to establishment of DENV within the vertebrate host.  This dissertation 
makes no attempt to investigate factors associated with the onset of disease symptoms or 
progression of disease severity, as our murine model is established as one of transmission, rather 
than disease recapitulation.  Summarized below are the results of each chapter, a discussion of 
their interrelatedness and relevance to previous works (of which I am a contributing author), and 
an indication of the future direction additional works should follow. 
 
6.2 Summary of results and comparison between works 
 In chapter 2, I conducted a high-throughput RNA-sequencing analysis of the effect that 
infection with different strains of DENV within serotype 2 has on gene expression within the 
salivary gland.  These proteins are highly relevant to the immunological context of DENV2 
establishment within the vertebrate and have been shown previously to be altered in an 
investigation of a single strain [1-3].  Similar to the previous protein studies, but on a grander 
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scale, we found differential expression at the transcript level of many thousands of different 
genes involved in a variety of cellular activities.  Notably relevant changes were found between 
the expression of known and putatively expectorated salivary proteins that differed based upon 
the strain of DENV2 (1232 versus 16803) infecting the salivary glands.  Importantly, both clade 
I and clade II aegyptins were identified in this study, whereas previous protein work missed the 
clade II aegyptin [2].  Both of these aegyptins were found to be expressed at different levels 
between the two virus strains tested, and importantly, only strain 1232 expressed these genes at 
levels different from control.  These results indicate the potential importance of aegyptins in the 
larger dynamics of DENV perpetuation and provide a greater rationale for their investigation in 
chapters 4 and 5. 
 In chapter 3, I conducted an in vivo study examining the impact of Ae. aegypti probing 
(i.e., salivation and mechanical damage) on establishment of DENV2, strain 1232 infection in a 
murine model of transmission.  This study utilized naïve (i.e., non-infectious) mosquitoes to 
probe mouse ears, and then the immediate intradermal inoculation of DENV into the probed 
locations.  By utilizing naïve mosquitoes, the results stem from the influence of steady-state, 
rather than virally-modified, saliva protein levels on the vertebrate response to DENV 
introduction.  This study provided evidence of global reductions in the immune response, with 
emphasis on the reduction of inflammatory and anti-viral gene transcript expression.  These 
immunological changes then associated with significantly enhanced magnitude and duration of 
viremia.  Higher concentrations of viremia have been associated empirically with increased 
acquisition rates and downstream prevalence of infectious mosquitoes, and a longer duration of 
viremia would provide additional opportunities for acquisition events by naïve, feeding 
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mosquitoes [4].  These results indicate for the first time that vector saliva can impact DENV 
establishment in the vertebrate in meaningful ways relevant to the perpetuation of the virus. 
 At this stage, our a priori knowledge of DENV-induced alterations to the salivary protein 
and now transcript profile, and the above observations on the impact of a steady-state salivary 
protein profile on DENV infection of the vertebrate required reconciliation.  In this dissertation, I 
provide and execute a two-stage experimental plan (in vitro and in vivo), consisting of chapters 4 
and 5, to account for the observations of salivary proteins in lower abundance upon DENV 
infection in the context of the observed benefits to DENV perpetuation caused by a steady-state 
salivary protein profile. 
 In chapter 4, I conducted an in vitro experiment testing the effects of individual, 
recombinant, Ae. aegypti salivary proteins on DENV2, strain 1232 infection in the human 
hematopoietic cell line, K562.  This study utilized three salivary proteins, of which two were 
known to belong to families found in lower abundance in the previous protein examination (an 
adenosine deaminase and an aegyptin), and one for which the protein relative abundance value is 
unknown (a C-type lectin).  Comparing to the transcript results from chapter 2, the adenosine 
deaminase and the aegyptin were again found to differ from control, whereas the C-type lectin of 
closest BLAST alignment was not found to differ (p>0.05) in transcript quantity from that of 
control, though other C-type lectins were.  Upon co-exposure of K562 cells to DENV and a 
salivary protein, DENV concentration in the supernatant (measured targeting RNA) was altered 
in interesting ways when compared to cells exposed to DENV alone.  DENV + aegyptin resulted 
in a significant decrease in the quantity of virus produced, suggesting a possible rationale for the 
lowering of aegyptin protein expectorated by DENV2-infected Ae. aegypti.  However, this 
alteration in DENV production was not seen in supernatants whose cells were exposed to 
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adenosine deaminase (the other lower-abundance salivary protein tested).  Interestingly, DENV 
+ C-type lectin resulted in a similar decrease to that of aegyptin co-exposed cells, which is 
important given that the protein abundance level of this C-type lectin in DENV-infected 
mosquitoes is currently unknown.  These results do not provide an immediate pattern for the 
postulation of an overarching statement about the nature of altered protein abundance and DENV 
infection of or perpetuation through the vertebrate.  Vertebrate immune responses are a larger 
network of interactions that far exceeds the scope of a single cell line.  Therefore, I moved into 
the more complex in vivo system, conducted in the next chapter. 
 In chapter 5, I chose the recombinant aegyptin protein to evaluate the impact of a lower-
abundance Ae. aegypti salivary protein on DENV2, strain 1232 infection of the vertebrate.  
DENV titers were examined in the inoculation sites and over time in circulation.  Intradermal co-
inoculation of DENV and aegyptin resulted in significantly decreased DENV titers in the 
inoculation sites at 48 hours post exposure when compared to inoculation of DENV alone.  This 
trend continued in the draining lymph nodes, and was observed (as significant) in circulation at 
the same time point.  The decreases in viral titers observed in the present study occurred 
contemporaneously with an increase to allergen-associated and anti-viral cytokines, including 
IFNγ, GMCSF, IL5, and IL6, as well as the increased likelihood of elevated eosinophils in 
circulation.  These immunological results are not surprising given the previous characterization 
of aegyptin (aka Aed a 3) as an allergen [5].  Looking at the present study from a reciprocal 
perspective, if a reduction of aegyptin in the salivary expectorate were to raise the viremia at the 
observed early time point above a threshold required for successful acquisition of DENV by 
naïve mosquitoes, this could increase the duration of human infectiousness.  Accordingly, high 
early DENV viremia titers have been shown to be a marker of the duration of infectiousness to 
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mosquitoes, and, as stated above, higher viremia titers are associated with higher acquisition 
rates and prevalence of infectious mosquitoes [4].  Additionally, it has been shown using 
mathematical models that an increased duration of human infectiousness of the index case upon 
entering a naïve human population results in an increase in the probability of DENV emergence 
within said population [6].  Therefore, these data could indicate the existence of a negative 
pressure on DENV perpetuation by at least one of the Ae. aegypti salivary proteins found in 
lower abundance upon DENV2 infection of the salivary glands, and thereby account for its 
lowered abundance. 
 
6.3 Conclusions and future direction 
 Together, the data presented in this dissertation inform on a complex and dynamic 
relationship between DENV, the vector, and the vertebrate host in which Ae. aegypti saliva plays 
an integral role.  Most studies of DENV transmission, infection, or disease pathogenesis do not 
involve or account for the contribution of mosquito saliva.  Even subtle changes due to mosquito 
saliva in the immunological response of the vertebrate, upon introduction of DENV or further 
along in the infection process, might have as yet uncharacterized consequences.  One 
consequence could be a differential progression to or risk of disease severity, as has been 
suggested by a correlative study of secondary DENV-infection, clinical patients in Thailand.  
This study found that seroreactivity to the protein Aed a 3 (i.e., aegyptin) associated with a mild 
clinical illness, whereas seroreactivity to the salivary protein apyrase associated with dengue 
hemorrhagic fever, and seroreactivity to a salivary D7 family member protein associated with 
clinical dengue disease regardless of severity [7].  Another consequence of not accounting for 
mosquito saliva during experimental investigations could arise during the development and 
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testing of DENV vaccine candidates.  For example, the Sanofi Pasteur vaccine candidate, 
currently the furthest along in clinical trial proceedings, is a promising tetravalent formulation, 
and yet generates only 60.8% overall efficacy and comparatively low protection against DENV 
serotype 2 [8].  While there are a great many factors that could impact the success of a vaccine, 
such as viral diversity and variation in individual, human immune responses, it is possible that 
earlier testing of vaccine formulations with vector saliva or salivary components could generate 
more efficacious results in the long term, especially when considering that mosquito saliva is 
present in all naturally acquired DENV infections.   
 Therefore, I propose that all future research into the establishment of arboviral infections 
and disease pathogenesis within the vertebrate include, or at least account for, some aspect of 
vector saliva.  Additional work in line with that of the present dissertation would include: 1) 
expanding upon chapter 2 with multiple specimen, individual target verification at the transcript 
and protein level, as well as including the additional three serotypes of DENV and other 
mosquito-transmitted viruses; 2) expanding chapter 3 through the characterization of additional 
time points, infiltrating cell types, and progression of virus from the site of inoculation to 
circulation, as well as the utilization of infectious mosquitoes and animals sensitized to mosquito 
saliva; 3) repetition of chapter 5 using other, individual salivary proteins; and 4) reconstructing 
the experimental setup of chapter 5 to utilize mosquitoes with a genetic- or RNAi-mediated 
depletion of individual proteins in a spot-feeding method of exposure, so that testing the impact 
of lowered protein abundance can be performed in a direct rather than reciprocal manner.  
Performing future experimentation in this manner would undeniably improve the body of 
knowledge regarding DENV perpetuation. 
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APPENDIX 3 
DATA SUPPLEMENT FROM CHAPTER 3 
 
Supplemental Table 3.1: SABiosciencs RT2 Profiler PCR Arrays - TLR, RLR, and NLR 
transcript results. 
   
Transcription Factors Fold-
regulation 
Gene name 
Elk1 -2.96 ELK1, member of ETS oncogene family 
Fos -1.67 FBJ osteosarcoma oncogene 
Irf1  1.60 Interferon regulatory factor 1 
Irf3 -1.59 Interferon regulatory factor 3 
Irf5  1.84 Interferon regulatory factor 5 
Irf7  1.45 Interferon regulatory factor 7 
Jun  2.00 Jun oncogene 
Nfkb1  1.42 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1, p105 
Nfkb2 -1.77 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2, p49/p100 
Nfrkb  1.29 Nuclear factor related to kappa B binding protein 
Nr2c2  2.31 Nuclear receptor subfamily 2, group C, member 2 
Ppara -1.79 Peroxisome proliferator activated receptor alpha 
Rel  3.81 Reticuloendotheliosis oncogene 
Rela  3.40 V-rel reticuloendotheliosis viral oncogene homolog A 
(avian) 
Stat1 -1.57 Signal transducer and activator of transcription 1 
Receptors   
Aim2 -1.57 Absent in melanoma 2 
Cd14  1.73 CD14 antigen 
Clec4e -3.65 C-type lectin domain family 4, member e 
Ddx58  2.19 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
Dhx58 -4.20 DEXH (Asp-Glu-X-His) box polypeptide 58 
Ifih1 -12.23 Interferon induced with helicase C domain 1 
Ifnar1 -2.25 Interferon (alpha and beta) receptor 1 
Il1r1  1.26 Interleukin 1 receptor, type I 
Il6ra  1.19 Interleukin 6 receptor, alpha 
Muc13 -3.63 Mucin 13, epithelial transmembrane 
Nlrp3 -2.70 NLR family, pyrin domain containing 3 
Nod2 -3.79 Nucleotide-binding oligomerization domain containing 2 
Tlr1 -4.53 Toll-like receptor 1 
Tlr2  1.22 Toll-like receptor 2 
Tlr3 -1.51 Toll-like receptor 3 
Tlr4  1.24 Toll-like receptor 4 
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Tlr5  1.52 Toll-like receptor 5 
Tlr6 -2.45 Toll-like receptor 6 
Tlr7 -3.88 Toll-like receptor 7 
Tlr8 -1.59 Toll-like receptor 8 
Tlr9 -3.16 Toll-like receptor 9 
Tnfrsf1a  1.56 Tumor necrosis factor receptor superfamily, member 1a 
MAPKs   
Mapk1 -4.60 Mitogen-activated protein kinase 1 
Mapk3 -2.48 Mitogen-activated protein kinase 3 
Mapk8 -1.65 Mitogen-activated protein kinase 8 
Mapk9 -2.46 Mitogen-activated protein kinase 9 
Mapk14 -2.50 Mitogen-activated protein kinase 14 
Map2k1 -1.74 Mitogen-activated protein kinase kinase 1 
Map2k3  1.91 Mitogen-activated protein kinase kinase 3 
Map2k4  3.62 Mitogen-activated protein kinase kinase 4 
Map3k1 -1.36 Mitogen-activated protein kinase kinase kinase 1 
Map3k7  1.21 Mitogen-activated protein kinase kinase kinase 7 
Enzymes   
Btk -1.19 Bruton agammaglobulinemia tyrosine kinase 
Casp1 -4.60 Caspase 1 
Casp8  1.26 Caspase 8 
Chuk  1.72 Conserved helix-loop-helix ubiquitous kinase 
Ctsb -2.02 Cathepsin B 
Ctsl -2.21 Cathepsin L 
Ctss -1.64 Cathepsin S 
Cyld -2.85 Cylindromatosis (turban tumor syndrome) 
Dak -1.25 Dihydroxyacetone kinase 2 homolog (yeast) 
Ddx3x -1.35 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-
linked 
Eif2ak2  1.20 Eukaryotic translation initiation factor 2-alpha kinase 2 
Irak1 -1.75 Interleukin-1 receptor-associated kinase 1 
Irak2  1.36 Interleukin-1 receptor-associated kinase 2 
Pin1 -2.57 Protein (peptidyl-prolyl cis/trans isomerase) NIMA-
interacting 1 
Ptgs2  1.92 Prostaglandin-endoperoxide synthase 2 
Ripk1  1.31 Receptor (TNFRSF)-interacting serine-threonine kinase 1 
Ripk2 -1.09 Receptor (TNFRSF)-interacting serine-threonine kinase 2 
Tbk1 -1.56 TANK-binding kinase 1 
Trim25 -2.28 Tripartite motif-containing 25 
Ube2n -1.72 Ubiquitin-conjugating enzyme E2N 
Ube2v1  1.00 Ubiquitin-conjugating enzyme E2 variant 1 
Cytokines and 
chemokines 
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Ccl2  1.17 Chemokine (C-C motif) ligand 2 
Ccl3 -3.84 Chemokine (C-C motif) ligand 3 
Ccl4 -2.68 Chemokine (C-C motif) ligand 4 
Ccl5 -3.39 Chemokine (C-C motif) ligand 5 
Csf2 -1.33 Colony stimulating factor 2 (granulocyte-macrophage) 
Csf3 -1.41 Colony stimulating factor 3 (granulocyte) 
Cxcl10 -2.86 Chemokine (C-X-C motif) ligand 10 
Ifnb1 -4.07 Interferon beta 1, fibroblast 
Ifng -6.13 Interferon gamma 
Il1a -1.16 Interleukin 1 alpha 
Il1b 3.26 Interleukin 1 beta 
Il2 -4.83 Interleukin 2 
Il6  1.33 Interleukin 6 
Il10 -1.09 Interleukin 10 
Il12a -3.73 Interleukin 12A 
Il15 -1.99 Interleukin 15 
Il18 -1.10 Interleukin 18 
Lta  2.01 Lymphotoxin A 
Tnf -2.08 Tumor necrosis factor 
Activators, Inhibitors, 
& Adaptors 
  
Agfg1  1.96 ArfGAP with FG repeats 1 
Atg12 -1.36 Autophagy-related 12 (yeast) 
Atg5  1.22 Autophagy-related 5 (yeast) 
Azi2 -2.09 5-azacytidine induced gene 2 
Card9 -1.48 Caspase recruitment domain family, member 9 
Cd40 -4.51 CD40 antigen 
Cd80 -1.14 CD80 antigen 
Cd86 -1.23 CD86 antigen 
Cebpb -1.08 CCAAT/enhancer binding protein (C/EBP), beta 
Cnpy3 -1.43 Canopy 3 homolog (zebrafish) 
Fadd -2.01 Fas (TNFRSF6)-associated via death domain 
Hmgb1  1.12 High mobility group box 1 
Hras1 -1.03 Harvey rat sarcoma virus oncogene 1 
Hsp90aa1 -1.08 Heat shock protein 90, alpha (cytosolic), class A member 
1 
Hspa1a  3.79 Heat shock protein 1A 
Hspd1 -1.05 Heat shock protein 1 (chaperonin) 
Ikbkb -1.72 Inhibitor of kappaB kinase beta 
Isg15 -4.26 ISG15 ubiquitin-like modifier 
Ly86  1.28 Lymphocyte antigen 86 
Ly96 -1.32 Lymphocyte antigen 96 
Mapk8ip3 -1.13 Mitogen-activated protein kinase 8 interacting protein 3 
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Mavs -2.10 Mitochondrial antiviral signaling protein 
Mefv -3.10 Mediterranean fever 
Myd88 -1.62 Myeloid differentiation primary response gene 88 
Nfkbia  2.78 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha 
Nfkbib  1.49 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, beta 
Nfkbil1 -1.45 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor-like 1 
Peli1  2.46 Pellino 1 
Pglyrp1 -1.80 Peptidoglycan recognition protein 1 
Pstpip1 -1.08 Proline-serine-threonine phosphatase-interacting protein 
1 
Pycard -2.24 PYD and CARD domain containing 
Spp1  1.52 Secreted phosphoprotein 1 
Sugt1 -1.16 SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 
Tank -2.77 TRAF family member-associated Nf-kappa B activator 
Tbkbp1 -2.55 TBK1 binding protein 1 
Ticam1 -2.24 Toll-like receptor adaptor molecule 1 
Ticam2  1.63 Toll-like receptor adaptor molecule 2 
Tirap -1.27 Toll-interleukin 1 receptor (TIR) domain-containing 
adaptor protein 
Tnfaip3  1.40 Tumor necrosis factor, alpha-induced protein 3 
Tollip -1.36 Toll interacting protein 
Tradd -1.71 TNFRSF1A-associated via death domain 
Traf3  1.56 Tnf receptor-associated factor 3 
Traf6  1.49 Tnf receptor-associated factor 6 
   
   
 Red values indicate a greater than 2-fold up-regulation of expression. 
 Blue values indicate a greater than 2-fold down-regulation of 
expression. 
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APPENDIX 4 
DATA SUPPLEMENT FROM CHAPTER 5 
 
Supplemental Table 5.1: Additional comparisons of circulating leukocyte percents (counts) at 48 
hours post inoculation in percents (counts).  Comparisons of each leukocyte were performed 
using odds ratios and significance is indicated by an asterisk (p≤0.05). 
 
  
95% CI 
  Lymphocyte Estimate Lower Upper Pr > |t| 
 A vs AV 2.019 1.488 2.74 0.0006 * 
A vs M 1.581 1.148 2.178 0.0148 * 
A vs V 2.223 1.639 3.016 0.0002 * 
AV vs M 0.783 0.6 1.023 0.0963 
 AV vs V 1.101 0.859 1.412 0.4603 
 M vs V 1.406 1.077 1.836 0.0263 * 
      
  
95% CI 
  Neutrophil Estimate Lower Upper Pr > |t| 
 A vs AV 0.369 0.251 0.545 0.0002 * 
A vs M 0.486 0.323 0.732 0.0042 * 
A vs V 0.439 0.297 0.65 0.0012 * 
AV vs M 1.317 0.974 1.78 0.0969 
 AV vs V 1.188 0.898 1.571 0.2482 
 M vs V 0.902 0.664 1.226 0.5221 
 
      
  
95% CI 
  Monocyte Estimate Lower Upper Pr > |t| 
 A vs AV 1.15 0.733 1.803 0.5528 
 A vs M 1.468 0.895 2.407 0.1523 
 A vs V 0.552 0.366 0.834 0.0143 * 
AV vs M 1.276 0.812 2.006 0.3096 
 AV vs V 0.48 0.335 0.688 0.0015 * 
M vs V 0.376 0.249 0.57 0.0005 * 
      
  
95% CI 
  Eosinophil Estimate Lower Upper Pr > |t| 
 A vs AV 0.702 0.352 1.403 0.3352 
 A vs M 0.533 0.267 1.063 0.0973 
 A vs V 1.694 0.751 3.821 0.226 
 AV vs M 0.759 0.444 1.298 0.3322 
 AV vs V 2.412 1.212 4.799 0.0262 * 
M vs V 3.178 1.6 6.312 0.0057 * 
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